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PS3 ASA REGULATOR OF CELL 
DIFFERENTIATION 
This application is a non-provisional application of pro 
visional Serial No. 60/051,549, filed Jul. 2, 1997. 
The government may own certain rights in this invention 
pursuant to a grant number IBN-9630621 from the National 
Science Foundation. 
BACKGROUND OF THE INVENTION 
A. Field of the Invention 
The present invention relates generally to the fields of 
oncology, embryology, molecular biology and genetics. 
More Specifically, the invention relates to the tumor biology 
of p53 mutants, molecules that interact with p53, and agents 
that are able to block p53-related defects in cellular differ 
entiation. 
B. Description of Related Art 
Many mutant p53 alleles are oncogenic, and p53 was in 
fact first thought to be an oncogene as the first clones 
isolated corresponded to mutant forms expressed in immor 
talized cell lines. Expression of mutant p53 immortalizes 
primary fibroblasts, and in combination with mutant ras, 
transforms such cells (Jenkins et al., 1984; Parada et al., 
1984; Eliyahu et al., 1985). Normal p53, however, functions 
as a tumor Suppressor and its overexpression can inhibit the 
growth of various tumor cell lines and can block the trans 
forming activity of a variety of oncogenes (Finlay et al., 
1989; Donehower and Bradley, 1993). 
p53 possesses Several different biochemical activities, 
including transcriptional activation and repression, Single 
stranded DNA binding, and interaction with several heter 
ologous proteins (Donehower and Bradley, 1993; Gottlieb 
and Oren, 1996; Haffner and Oren, 1995). These activities 
regulate a diverse array of biological processes, for example 
cell cycle transitions, apoptosis, and response to DNA 
damage (Donehower and Bradley, 1993; Gottlieb and Oren, 
1996; Haffner and Oren, 1995). Elimination of p53 activity 
is thought to contribute to the initiation or progression of 
tumorigenesis by loss of cell cycle control, genomic 
instability, and the acquisition of novel properties, Such as 
resistance to hypoxia (Donehower and Bradley, 1993; Got 
tlieb and Oren, 1996; Haffner and Oren, 1995; Graeber et al., 
1996). Given this involvement in numerous fundamental 
processes, it is quite Surprising that p53-null mice develop to 
term in the majority of cases (Donehower et al., 1992; 
Armstrong et al., 1995; Sah et al., 1995). However, p53 is 
expressed during early murine development in a pattern 
consistent with a role in differentiation (Schmid et al., 1991; 
Komarova et al., 1997), and the precise regulation of expres 
Sion appears to be essential for normal development (Montes 
de Oca Luna et al., 1995; Jones et al., 1995). 
Thus, although it is clear that p53 plays a key role in 
tumor development, and may be involved in differentiation 
as well, the particular mechanisms by which this molecule 
functions remain undefined. Moreover, it is unclear whether 
the role play by p53 in these two activities is related. 
SUMMARY OF THE INVENTION 
The present invention involves the role of p53 in the 
differentiation of embryonic tissues. More particularly, the 
present invention provides methods of the blocking of p53 
function in embryonic tissues, and the use of these tissueS as 
Screening tools for Substances that are capable of overcom 











in Vivo. These assays Serve as a model for possible cancer 
therapeutics. In addition, methods for identifying additional 
cellular components that interact p53 or p53-related path 
ways are provided. 
There is provided in the present invention a method of 
Screening for agents that inhibit a p53-related block of 
embryonic cell differentiation comprising the Steps of pro 
Viding an undifferentiated embryonic cell; blocking the 
function of p53 in the cell such that the cell fails to 
differentiate, contacting the cell with a candidate agent; and 
comparing the differentiation of the contacted cell after the 
contacting with the differentiation of the cell in the absence 
of the candidate agent whereby an increase in differentiation 
indicates that the candidate agent is an inhibitor of the 
p53-related block of differentiation. 
In particular embodiments, the method further comprises 
the Step of comparing the differentiation of the cell after the 
contacting with the differentiation of the undifferentiated 
embryonic cell. In more particular embodiments, the cell 
may be an amphibian cell. In Still more particular 
embodiments, amphibian cell is a Xenopus laevis cell. In 
other specific embodiments, the cell is an insect cell. In more 
particular embodiments, the insect cell is a Drosophila 
melanogaster cell. In further embodiments, it is contem 
plated that the cell may be a mammalian cell. In specific 
embodiments the cell may be a mouse cell, in alternate 
embodiments the mammalian cell is a human cell. 
In particular aspects, the blocking is achieved by intro 
ducing into the cell a nucleic acid encoding a dominant 
negative mutant of p53. More specifically, the introducing 
may be achieved via electroporation, microinjection, par 
ticle bombardment, liposome transfer or viral infection. In 
certain aspects, the nucleic acid is a DNA; in other aspects, 
the nucleic acid is an RNA. 
In certain specific embodiments, the blocking is achieved 
by introducing into the cell a nucleic acid encoding double 
minute-2 or a ortholog thereof. In other embodiments, the 
blocking is achieved by introducing into the cell an antisense 
nucleic acid for p53. In Specific aspects, the candidate agent 
is a nucleic acid. In other embodiments, the candidate agent 
is polypeptide. In particular embodiments, the candidate 
agent is produced by a neighboring cell. In other 
embodiments, the neighboring cell is a Second undifferen 
tiated embryonic cell into which the candidate agent has 
been introduced. 
In particular aspects, the differentiation is determined by 
culture of the undifferentiated embryonic cell in vitro under 
conditions where the cell differentiates. 
More particularly the differentiation is determined by 
development of an embryo in vitro or in vivo. 
Also provided is a method for identifying genes involved 
in p53-mediated embryonic cell differentiation comprising 
the Steps of providing a plurality of undifferentiated DroSO 
phila melanogaster embryonic cells, contacting the cells 
with a gene encoding a dominant negative mutant of p53 
operably linked to a developmentally regulated promoter 
responsible for a given trait; mutagenizing the contacted 
cells, assessing development of the trait in the resulting flies, 
and determining the identity of a mutated cellular product in 
flies exhibiting trait development. 
In certain embodiments, the mutagenizing may comprise 
radiation of the cells. In other embodiments, the mutageniz 
ing may comprise contacting the cells with a DNA damaging 
agent. In Still further embodiments, the mutagenizing com 
prises introducing mRNA into the cells. 
In particular aspects of the present invention, the contact 
ing comprises microinjection of a P-element comprising the 
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mutant p53 gene and the promoter. In particular aspects, the 
promoter is the eyeless promoter and the trait is eye devel 
opment. 
In other aspects of the present invention, there is provided 
a method for identifying genes involved iri p53-mediated 
embryonic cell differentiation comprising the Steps of pro 
Viding a plurality of pluripotent embryonic Stem cells trans 
formed with a gene encoding a dominant negative mutant of 
p53 operably linked to an inducible promoter, contacting the 
cells with nucleic acid encoding a polypeptide and a factor 
that induces the inducible promoter, culturing the contacted 
cells under conditions permitting differentiation; and assess 
ing the differentiation of the cells, wherein differentiation in 
a cell identifies a polypeptide involved in p53-mediated cell 
differentiation. 
In preferred aspects, the method further comprises con 
tacting the cells with a plurality of nucleic acids encoding 
polypeptides. In certain embodiments, the plurality of 
nucleic acids is an expression vector library. 
In particular embodiments, the inducible promoter is the 
ecdysone response promoter and the factor is ecdysone. In 
alternate embodiments, the inducible promoter is the met 
allothionein promoter and the factor is a heavy metal. In yet 
another embodiment, the inducible promoter is the tetracy 
cline promoter and the factor is tetracycline. In Still another 
alternative embodiment, the inducible promoter is a heat 
Shock promoter and the factor is heat. 
In particular aspects, the conditions include culture with 
out LIF. In preferred embodiments, the differentiation com 
prises formation of hematopoietic cells, macrophages and 
cardiac cells. In other embodiments, the conditions further 
include culture on bacterial grade plastic and the differen 
tiation comprises formation of erythroid cells. In other 
embodiments the conditions further include culture with 
retinoic acid and the differentiation comprises formation of 
neural cells. In Still another embodiments, the conditions 
further include culture with erythropoietin and the differen 
tiation comprises formation of hematopoietic cells. In a 
further alternative embodiments, the conditions further 
include culture with interleukin 3 and the differentiation 
comprises formation of macrophages, neutrophils and mast 
cells. In yet another alternative, the conditions further 
include culture with interleukin 3, interleukin 1, and mac 
rophage colony Stimulating factor or granulocyte 
macrophage colony Stimulating factor and the differentiation 
comprises macrophages. In other embodiments, the condi 
tions further include culture with bone morphogenetic pro 
tein 4 and the differentiation comprises hematopoietic cells. 
In particular aspects, the the embryonic Stem cells are 
mammalian cells. The mammalian cells may be mouse cells. 
In those embodiments, where the cells are mouse cells, the 
culturing may comprise injected the contacted cells into a 
mouse blastocyst and implanting the blastocyst in a foster 
mother. Alternatively, the mammalian cells are human cells. 
In other preferred embodiments, the embryonic stem cells 
are amphibian cells. In particular embodiments, the amphib 
ian cells are Xenopus laevis cells. In an alternate preferred 
embodiments the embryonic Stem cells are insect cells. 
More particularly the insect cells may be Drosophila mela 
nogaster cells. 
Other objects, features and advantages of the present 
invention will become apparent from the following detailed 
description. It should be understood, however, that the 
detailed description and the Specific examples, while indi 
cating preferred embodiments of the invention, are given by 











cations within the Spirit and Scope of the invention will 
become apparent to those skilled in the art from this detailed 
description. 
BRIEF DESCRIPTION OF THE DRAWINGS 
The following drawings form part of the present Specifi 
cation and are included to further demonstrate certain 
aspects of the present invention. The invention may be better 
understood by reference to one or more of these drawings in 
combination with the detailed description of Specific 
embodiments presented herein: 
FIG. 1A, FIG. 1B, FIG. 1C and FIG. 1D. Expression of 
dominant-negative p53 inhibits differentiation and results in 
the formation of developmental tumors. FIG. 1A. Experi 
mental protocol. Xenopus embryos were fertilized in vitro. 
At the 32-cell Stage, a single blastomere was either 
co-injected with B-galactosidase and mutant p53 mRNAS, or 
injected with B-galactosidase alone. Embryos were injected 
into one side only, allowing the uninjected Side to act as an 
internal control for normal development. Injected embryos 
were reared to the Swimming tadpole Stage, fixed, and 
Stained to detect the presence of B-galactosidase activity. 
Cells expressing p53' and f-galactosidase (light blue) 
did not contribute to normal embryonic structures and 
clumped together into large cell masses, or tumors (arrows). 
FIG. 1B. Transverse section through an embryo injected 
with B-galactosidase and p53' mRNAs. The tumor is 
continuous with the Spinal cord and is partially covered by 
pigmented melanocytes (red arrows), as is the spinal cord. 
Note that the Somite ventral to the tumor is reduced in size 
compared to the Somite on the uninjected (control) side. 
Specimen stained with hematoxylin and eosin. FIG. 1C. 
Transverse Section through the same Specimen as in B, 
Stained with SytoX green to visualize nuclei. The tumor is 
nucleated and contains cells of approximately normal size. 
FIG. 1D. Transverse section through an embryo injected 
with p53'' and B-galactosidase mRNAS and stained with 
the neural-specific antibody 2G9 (dark purple histochemical 
Substrate). The spinal cord is strongly stained, but the tumor 
cells (black arrows, light blue/green Stain), including those 
intimately associated with the Spinal cord, do not express the 
antigen. A melanocyte associated with the tumor is indicated 
with a red arrow. 
FIG. 2A and FIG. 2B. Wild-type p53 rescues the mutant 
p53 phenotype. FIG. 2A-Embryo injected with 125 pg of 
p53' mRNA plus B-galactosidase mRNA and stained 
for B-galactosidase activity; cells expressing B-galactosidase 
(blue) clump together into distinct cell masses or tumors 
(arrow). FIG. 2B-Embryo injected with 125 pg. p53' 
plus 500 pg of human wild-type p53 and B-galactosidase as 
a lineage tracer; cells expressing B-galactosidase are distrib 
uted normally across the embryo and incorporated into 
normal tissues. 
FIG. 3A, FIG. 3B, FIG. 3C, FIG. 3D, FIG. 3E, FIG. 3F, 
FIG. 3G, and FIG. 3H. Morphology of developmental 
tumors (transverse sections). The left side of embryo was 
injected in all cases. Schematic representation of each panel 
is shown below in 3E-H. FIG. 3A p53'-induced 
tumor. The tumor bulges out from the lateral Surface of the 
Spinal cord. The Somite on the injected Side is restricted 
ventrally (compare to uninjected control Side). FIG. 
3B-p53'7-induced tumor. The tumor is continuous with 
the dorsal spinal cord and the overlying epidermis, and 
occupies much of an extracellular-matrix-filled Space lateral 
to the spinal cord where the somite is normally present. FIG. 
3C-p53'-'-induced tumor. The tumor is integrated into 
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the dorsal neural tube and extends ventrolaterally where 
Somite is normally present. FIG. 3D-Xdm-2 induced 
tumor. The tumor is integrated into the epidermis dorsal to 
the hindbrain. Tumors in all cases contain a high density of 
yolk platelets and appear to be undifferentiated. Scale bar= 
100 microns. Scale is similar in A-C. ecm=extracellular 
matrix. 
FIG. 4A and FIG. 4B. Developmental tumor associated 
with multiple tissues. Transverse section (FIG. 4A) and 
Schematic diagram (FIG. 4B) illustrating a tumor (in this 
case p53'-induced) which is associated closely with the 
neural tube, extends under the notochord and is associated 
with the pronephros on the opposite side of the embryo. The 
right side was injected with mutant p53 mRNA. The pres 
ence of tumor cells on both sides of the midline is probably 
a consequence of the movement of loosely adherent cells 
driven by normal morphogenetic movements, rather than the 
undifferentiated cells possessing any invasive properties. 
FIG. 5. Dominant-negative p53 does not inhibit the mid 
blastula transition. 4-cell Stage embryos were injected with 
p53' mRNA into all four cells (+ samples), control 
embryos were uninjected (- Samples). At Stage 6 (lane 1-2), 
p53' mRNA injected embryos (+) and uninjected 
embryos (-) both express low levels of EF-1a, but do not 
express goosecoid or brachyury. Following the MBT, at 
stage 10.5 (lane 4-5) and stage 13 (lane 6-7), EF-1a expres 
Sion is upregulated and Zygotic expression of goosecoid and 
brachyury commences equally in injected (+) and uninjected 
(-) embryos. -RT=no reverse transcriptase control. 
DETAILED DESCRIPTION OF THE 
PREFERRED EMBODIMENT 
Cancer accounts the death of over half a million people 
each year in the United States alone. The causes for cancer 
are multifactorial, however, it is known that aberrations in 
controlled cell death result in uncontrolled cell proliferation 
and hence contribute to many cancer. The p53 gene is well 
recognized as possessing tumor Suppressor capabilities and 
mutations in wild-type p53 are correlated to a variety of 
cancers. However, the interaction of p53 with other cellular 
factorS is not well characterized, and in fact, many of these 
factors remain undefined. It is not Surprising that, in light of 
the lack of Significant information on p53 function, there is 
an incomplete understanding of the pathways through which 
p53 regulates tumor development. 
A. The Present Invention 
The present inventors have examined the role of p53 in 
differentiation of cells as a way of better understanding the 
growth regulatory properties of this molecule. It now has 
been demonstrated that blocking p53 function in embryonic 
cells halts differentiation. By using different kinds of p53 
mutations and by differing blocks to p53 function, one can 
assess the different functional aspects of p53 as it relates to 
differentiation. Furthermore, one can use differentiation as a 
measure of different agents to overcome this p53-mediated 
block in differentiation. 
Certain biological Systems are particularly well-adapted 
to exploit this approach. For example, the developmental 
biology of Xenopus and Drosophila are extremely well 
characterized, easily reproduced, and Suitable for large Scale 
Screening methods. Murine Systems also provide a fruitful, 
if Somewhat more complex, System in which to explore the 
functions of p53. In addition, it is anticipated that human 
embryonic cells may be utilized in vitro for various of the 
experiments described herein. 
In general terms, the present invention decribes blocking 











blocking, or otherwise abrogating p53 activity. The differ 
entiation ability of the cells may be rescued by introducing 
a gene, gene product or phamaceutical compound which can 
bypass the mutant p53 mediated block and identifying those 
cells which have undergone differentiation in the presence of 
mutant p53. 
In particular, it is anticipated that one can Screen large 
numbers of potential pharmaceuticals, Small molecule 
libraries and expression libraries for active compounds. The 
compounds will be screened for their ability to permit 
differentiation of cells which otherwise remain undifferen 
tiated. The dysplastic nature of these cells is remarkably 
Similar to that of tumor cells arising from p53 defects, and 
thus the overcoming of this block appears, in certain aspects, 
analogous to treatment of tumors, although most conven 
tional treatments are designed to kill tumors, not correct 
defects. Thus, it is believed that the present invention 
provides a unique approach to the identification of factors, 
exogenous and endogenous, that can Serve as therapeutics 
for cancers and other developmentally-related diseases. 
B. p53 Polypeptides and Nucleic Acids Coding Therefor 
p53 currently is recognized as a tumor Suppressor gene 
(Montenarh, 1992). High levels of mutant p53 have been 
found in many cells transformed by chemical 
carcinogenesis, ultraViolet radiation, and Several viruses, 
including SV40. The p53 gene is a frequent target of 
mutational inactivation in a wide variety of human tumors 
and is already documented to be the most frequently 
mutated gene in common human cancers (Mercer, 1992). It 
is mutated in over 50% of human NSCLC (Hollestein et al., 
1991) and in a wide spectrum of other tumors. 
The p53 gene encodes a 393-amino-acid phosphoprotein 
that can form complexes with viral proteins Such as, large-T 
antigen and E1B. The protein is found in normal tissues and 
cells, but at concentrations which are minute by comparison 
with transformed cells or tumor tissue. Interestingly, wild 
type p53 appears to be important in regulating cell growth 
and division. Overexpression of wild-type p53 has been 
shown in Some cases to be anti-proliferative in human tumor 
cell lines. Thus, p53 can act as a negative regulator of cell 
growth (Weinberg, 1991) and may directly suppress uncon 
trolled cell growth or activate genes that Suppress this 
growth. Thus, absence or inactivation of wild-type p53 may 
contribute to transformation. However, Some Studies indi 
cate that the presence of mutant p53 may be necessary for 
full expression of the transforming potential of the gene. 
Casey and colleagues have reported that transfection of 
DNA encoding wild-type p53 into two human breast cancer 
cell lines restores growth Suppression control in Such cells 
(Casey et al., 1991). A similar effect has also been demon 
Strated on transfection of wild-type, but not mutant, p53 into 
human lung cancer cell lines (Takahasi et al., 1992). p53 
appears dominant over the mutant gene and will Select 
against proliferation when transfected into cells with the 
mutant gene. Normal expression of the transfected p53 does 
not affect the growth of cells with endogenous p53. Thus, 
Such constructs might be taken up by normal cells without 
adverse effects. It is thus proposed that the treatment of 
p53-associated cancers with wild type p53 will reduce the 
number of malignant cells or their growth rate. Clinical. data 
using retroviral p53 to treat cancer also have been presented 
(Roth et al., 1996) 
i) p53 in Differentiation 
Observations from both transgenic mice and tissue culture 
experiments have raised the possibility that p53 may be 
required for normal differentiation in Some cell types. Fore 
most among these observations is the high incidence of 
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neural tube and craniofacial abnormalities observed in p53 
null mice (Armstrong et al., 1995; Sah et al., 1995). Other 
observations consistent with a developmental role include 
the under-representation of transgenic mice in the offspring 
of transgenics containing mutant p53 alleles (Harvey et al., 
1995) and a possible involvement of p53 in B-cell differ 
entiation (Hall and Lane, 1997; Rotter et al., 1994). These 
results Suggest that either p53 plays a role in Some aspect of 
differentiation, or that the lack of p53 activity results in the 
accumulation of genetic lesions which in turn inhibit normal 
development. 
The Xenopus embryo provides an excellent model for the 
rapid development of embryonic cells. Xenopus p53 is 
biochemically and biologically similar to human p53 (Cox et 
al., 1994), and Xenopus embryos contain a ubiquitous 
maternal stockpile of p53 mRNA, and protein (Hoever et al., 
1994; Tchang et al., 1993). Elimination of protein function 
in Xenopus has been most effectively achieved by overex 
pression of dominant-negative mutants (Hemmatti 
Brivanlou and Melton, 1992, Levine et al., 1994, Molenaar 
et al., 1996; Dong et al., 1996), and many mutant forms of 
p53 have been shown to act in a dominant-negative manner 
(Baker et al., 1989; Nigro et al., 1989). 
ii) Methods of InhibitingpS3 Function 
According to the present invention, one will Seek to block 
the expression and/or function of p53 as it relates to differ 
entiation of embryonic cells. In So doing, cells engineered or 
treated in this manner will have a p53-mediated block in 
differentiation. This accomplished, it then remains to deter 
mine what factors are capable of overriding this effect. 
Missense mutations are common for the p53 gene and are 
essential for the transforming ability of the oncogene. A 
Single genetic change prompted by point mutations can 
create carcinogenic p53. Unlike other oncogenes, however, 
p53 point mutations are known to occur in at least 30 distinct 
codons, often creating dominant alleles that produce shifts in 
cell phenotype without a reduction to homozygosity. 
Additionally, these “dominant negative' alleles appear to be 
tolerated in the organism and passed on in the germ line. 
Various mutant alleles appear to range from minimally 
dysfunctional to Strongly penetrant, dominant negative alle 
les (Weinberg, 1991). 
In one embodiment, blocking of p53 function is achieved 
by providing to a cell containing a wild-type p53 gene a 
dominant negative mutant of p53. Unlike Some p53 mutants, 
which merely are inactivated (i.e., lacking the normal tumor 
Suppressor function) and can be rescued by provision of a 
wild-type gene, dominant negative mutants will “override' 
the actions of a wild-type gene. Thus, no "knock-out' or 
other anti-p53 modifications are required, only the provision 
of a dominant negative mutant. 
Typically, this is achieved by transforming a cell 
(discussed further, below) with a gene encoding a dominant 
negative mutant of p53. Below (Table 1), there is listed a 
Series of p53 mutants that function as dominant negative 
mutantS. 
TABLE 1. 
Dominant Negative p53 Mutants 
Mutation Location Classification 
Arg->His 175 dominant negative 
Arg-Trp 248 dominant negative 
Arg->Thr 28O dominant negative 
Another method of blocking p53 function, in a manner 











binding protein that will inactivate wild-type p53 that is 
present in the embryonic cell. Such a binding protein is the 
so-called “double minute-2,” a oncoprotein that binds to and 
inhibits the transcriptional activation domain of p53. 
Orthologs have been identified in the mouse (mdm-2), 
Xenopus (Xdm-2) and human (Oliner et al., 1992). MDM-2 
also can inhibit p53 activity by targeting the p53 protein for 
ubiquitin-mediated degradation (Kubbutat et al., 1997; Haupt 
et al., 1997). 
Inhibition of p53 activity also may be achieved by expres 
Sion of p53-binding proteins encoded by viral oncogenes. 
One Such protein is the E6 protein of human papillomvirus 
types 16 or 18. This protein binds to p53, and in combination 
with the a cellular protein, the 100 kid E6 assosciated protein 
(E6-AP), targets p53 protein for ubiquitin-mediated degra 
dation (Scheffner et al., 1990; 1993). One could envision 
expressing either E6 alone or E6 in addition to E6-AP in 
order to inhibit p53 activity. Likewise, the adenovirus 55K 
early 1B (E1B 55K) protein binds to p53 and inhibits its 
transcriptional activation activity and its tumor Suppressor 
functions (Sarnow et al., 1982; Yew and Berk, 1992). 
Expression of EIB therefore also may be used to inhibit p53 
activity in the present invention. 
In various other embodiments, one may utilize antisense 
methodologies to inhibit the expression of p53. AntiSense 
methodology takes advantage of the fact that nucleic acids 
tend to pair with “complementary Sequences. By 
complementary, it is meant that polynucleotides are those 
which are capable of base-pairing according to the Standard 
Watson-Crick complementarity rules. That is, the larger 
purines will base pair with the Smaller pyrimidines to formn 
combinations of guanine paired with cytosine (G.C) and 
adenine paired with either thymine (AT) in the case of 
DNA, or adenine paired with uracil (AU) in the case of 
RNA. Inclusion of leSS common bases Such as inoSine, 
5-methylcytosine, 6-methyladenine, hypoxanthine and oth 
erS in hybridizing Sequences does not interfere with pairing. 
Targeting double-stranded (ds) DNA with polynucle 
otides leads to triple-helix formation; targeting RNA will 
lead to double-helix formation. AntiSense polynucleotides, 
when introduced into a target cell, Specifically bind to their 
target polynucleotide and interfere with transcription, RNA 
processing, transport, translation and/or Stability. AntiSense 
RNA constructs, or DNA encoding such antisense RNA's, 
may be employed to inhibit gene transcription or translation 
or both within a host cell, either in vitro or in vivo, Such as 
within a host animal, including a human Subject. 
AS Stated above, “complementary or “antisense' means 
polynucleotide Sequences that are Substantially complemen 
tary over their entire length and have very few base mis 
matches. For example, Sequences of fifteen bases in length 
may be termed complementary when they have complemen 
tary nucleotides at thirteen or fourteen positions. Naturally, 
Sequences which are completely complementary will be 
Sequences which are entirely complementary throughout 
their entire length and have no base mismatches. Other 
Sequences with lower degrees of homology also are con 
templated. For example, an antisense construct which has 
limited regions of high homology, but also contains a 
non-homologous region (e.g., ribozyme; see below) could 
be designed. These molecules, though having less than 50% 
homology, would bind to target Sequences under appropriate 
conditions. 
Yet another manner of disrupting normal p53 function in 
a cell is to provide that cell with a ribozyme construct that 
cleaves wild-type p53 transcripts, thereby preventing trans 
lation of a complete p53 product. Although proteins tradi 
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tionally have been used for catalysis of nucleic acids, 
another class of macromolecules has emerged as useful in 
this endeavor. Ribozymes are RNA-protein complexes that 
cleave nucleic acids in a site-specific fashion. Ribozyme S 
have specific catalytic domains that possess endonuclease 
activity (Kim and Cech, 1987; Gerlach et al., 1987; Forster 
and Symons, 1987). For example, a large number of 
ribozymes accelerate phosphoester transfer reactions with a 
high degree of Specificity, often cleaving only one of Several 
phosphoesters in an oligonucleotide Substrate (Cech et al., 
1981; Michel and Westhof, 1990; Reinhold-Hurek and 
Shub, 1992). This specificity has been attributed to the 
requirement that the Substrate bind via Specific base-pairing 
interactions to the internal guide sequence (“IGS") of the 
ribozyme prior to chemical reaction. 
Ribozyme catalysis has primarily been observed as part of 
Sequence-specific cleavage/ligation reactions involving 
nucleic acids (Joyce, 1989; Cech et al., 1981). For example, 
U.S. Pat. No. 5,354,855 reports that certain ribozymes can 
act as endonucleases with a Sequence Specificity greater than 
that of known ribonucleases and approaching that of the 
DNA restriction enzymes. Thus, Sequence-specific 
ribozyme-mediated inhibition of gene expression may be 
particularly Suited to therapeutic applications (Scanlon et al., 
:1991; Sarver et al., 1990). Recently, it was reported that 
ribozymes elicited genetic changes in Some cells lines to 
which they were applied; the altered genes included the 
oncogenes H-ras, c-fos and genes of HIV. Most of this work 
involved the modification of a target mRNA, based on a 
Specific mutant codon that is cleaved by a specific ribozyme. 
C. Expression Constructs 
According to the present invention, various genes will be 
expressed, both in vitro and in Vivo. Synthetic mRNA 
encoding a gene product of interest, or a pool of Synthetic 
mRNAS generated from a pool of template DNAS can be 
Synthesized in vitro using purified bacterial or bactiophage 
RNA polymerases. Such mRNA(s) can be introduced into 
cells directly by microinjection or by any of the transfection 
methods used to introduce DNA into a cell. In order to 
enhance the translation of synthetic mRNA in a cell it is 
important to Synthesize the mRNA incorporating a 5' cap. 
cDNAS to be translated into mRNA are also often cloned 
into specific vectors which contain 5' and 3' untranslated 
Sequences from efficiently translated mRNAS to enhance the 
translational efficiency of the synthesized mRNA. 
Sequences which enhance the polyadenylation of introduced 
mRNAS are also Sometimes incorporated into vectors used 
for in vitro mRNA synthesis. 
Expression of genes of interest calls for the use of 
expression vectors which provide for the replication, ampli 
fication and expression of constructs contained therein. 
Replication and amplification usually require an origin of 
replication. Expression requires appropriate Signals in the 
vectors, and which include various regulatory elements, 
Such as enhancers/promoters from both viral and mamma 
lian Sources that drive expression of the genes of interest in 
host cells. Elements designed to optimize messenger RNA 
stability and translatability in host cells also are defined. The 
conditions for the use of a number of dominant drug 
Selection markers for establishing permanent, Stable cell 
clones expressing the products are also provided, as is an 
element that links expression of the drug Selection markers 
to expression of the polypeptide. 
i) Regulatory Elements 
Throughout this application, the term "expression con 
Struct” is meant to include any type of genetic construct 











part or all of the nucleic acid encoding Sequence is capable 
of being transcribed. The transcript may be translated into a 
protein, but it need not be. In certain embodiments, expres 
Sion includes both transcription of a gene and translation of 
mRNA into a gene product. In other embodiments, expres 
Sion only includes transcription of the nucleic acid encoding 
a gene of interest. 
In preferred embodiments, the nucleic acid encoding a 
gene product is under transcriptional control of a promoter. 
A “promoter” refers to a DNA sequence recognized by the 
Synthetic machinery of the cell, or introduced Synthetic 
machinery, required to initiate the Specific transcription of a 
gene. The phrase “under transcriptional control’ means that 
the promoter is in the correct location and orientation in 
relation to the nucleic acid to control RNA polymerase 
initiation and expression of the gene. 
The term promoter will be used here to refer to a group of 
transcriptional control modules that are clustered around the 
initiation site for RNA polymerase II. Much of the thinking 
about how promoters are organized derives from analyses of 
several viral promoters, including those for the HSV thy 
midine kinase (tk) and SV40 early transcription units. These 
Studies, augmented by more recent work, have shown that 
promoters are composed of discrete functional modules, 
each consisting of approximately 7-20 bp of DNA, and 
containing one or more recognition Sites for transcriptional 
activator or repressor proteins. 
At least one module in each promoter functions to posi 
tion the start site for RNA synthesis. The best known 
example of this is the TATA box, but in some promoters 
lacking a TATA box, Such as the promoter for the mamma 
lian terminal deoxynucleotidyl transferase gene and the 
promoter for the SV40 late genes, a discrete element over 
lying the Start Site itself helps to fix the place of initiation. 
Additional promoter elements regulate the frequency of 
transcriptional initiation. Typically, these are located-in the 
region 30-110 bp upstream of the Start Site, although a 
number of promoters have recently been shown to contain 
functional elements downstream of the start site as well. The 
spacing between promoter elements frequently is flexible, So 
that promoter function is preserved when elements are 
inverted or moved relative to one another. In the tk promoter, 
the Spacing between promoter elements can be increased to 
50 bp apart before activity begins to decline. Depending on 
the promoter, it appears that individual elements can func 
tion either co-operatively or independently to activate tran 
Scription. 
The particular promoter employed to control the expres 
Sion of a nucleic acid Sequence of interest is not believed to 
be important, So long as it is capable of direction the 
expression of the nucleic acid in the targeted cell. Thus, 
where a human cell is targeted, it is preferable to position the 
nucleic acid coding region adjacent to and under the control 
of a promoter that is capable of being expressed in a human 
cell. Generally Speaking, Such a promoter might include 
either a human or viral promoter. 
In various embodiments, the human cytomegalovirus 
(CMV) immediate early gene promoter, the SV40 early 
promoter, the Rous Sarcoma virus long terminal repeat, rat 
insulin promoter and glyceraldehyde-3-phosphate dehydro 
genase can be used to obtain high-level expression of the 
coding Sequence of interest. The use of other viral or 
mammalian cellular or bacterial phage promoters which are 
well-known in the art to achieve expression of a coding 
Sequence of interest is contemplated as well, provided that 
the levels of expression are Sufficient for a given purpose. By 
employing a promoter with well-known properties, the level 
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and pattern of expression of the protein of interest following 
transfection or transformation can be optimized. Further, 
Selection of a promoter that is regulated in response to 
Specific physiologic Signals can permit inducible expression 
of the gene product. 
In particular embodiments, the present invention encom 
passes the use of Drosophila promoterS Such as eyeless. In 
this context, the promoters are associated with development 
of various traits and hence may be classified as “tissue 
Specific' promoters, i.e., is expressed in certain tissues and 
not others. 
Enhancers are genetic elements that increase transcription 
from a promoter located at a distant position. On the same 
molecule of DNA. Enhancers are organized much like 
promoters. That is, they are composed of many individual 
elements, each of which binds to one or more transcriptional 
proteins. 
The basic distinction between enhancers and promoters is 
operational. An enhancer region as a whole must be able to 
Stimulate transcription at a distance; this need not be true of 
a promoter region or its component elements. On the other 
hand, a promoter must have one or more elements that direct 
initiation of RNA synthesis at a particular site and in a 
particular orientation, whereas enhancers lack these speci 
ficities. Promoters and enhancers are. Often overlapping and 
contiguous, often Seeming to have a very Similar modular 
organization. Any promoter/enhancer combination (as per 
the Eukaryotic Promoter Data Base EPDB) could also be 
used to drive expression of the gene. 
Where a cDNA insert is employed, one will typically 
desire to include a polyadenylation signal to effect proper 
polyadenylation of the gene transcript. The nature of the 
polyadenylation signal is not believed to be crucial to the 
Successful practice of the invention, and any Such Sequence 
may be employed such as human growth hormone and SV40 
polyadenylation Signals. Also contemplated as an element of 
the expression cassette is a terminator. These elements can 
Serve to enhance message levels and to minimize read 
through from the cassette into other Sequences. 
ii) Markers 
In certain embodiments of the invention, the cells contain 
nucleic acid constructs of the present invention, a cell may 
be identified in vitro or in vivo by including a marker in the 
expression construct. Such markers would confer an iden 
tifiable change to the cell permitting easy identification of 
cells containing the expression construct. Usually, the inclu 
Sion of a drug Selection marker aids in cloning and in the 
Selection of transformants, for example, genes that confer 
resistance to neomycin, puromycin, hygromycin, DHFR, 
GPT. Zeocin and histidinol are useful selectable markers. 
Alternatively, enzymes Such as herpes simplex virus thymi 
dine kinase (tk) or chloramphenicol acetyltransferase (CAT) 
may be employed. Alternatively, the markers may be utilized 
Simply for identification purpose. Enzymes that provide 
fluorime tric or calorime tric changes include 
B-galactosidase, green fluorescent protein and luciferase. 
Further examples of markers are well known to one of skill 
in the art. 
iii) Multigene Constructs and IRES 
In certain embodiments of the invention, the use of 
internal ribosome entry site (IRES) elements are used to 
create multigene, or polycistronic, messages. IRES elements 
are able to bypass the ribosome Scanning model of 5' 
methylated Cap dependent translation and begin translation 
at internal sites (Pelletier and Sonenberg, 1988). IRES 
elements from two members of the picanovirus family (polio 











and Sonenberg, 1988), as well an IRES from a mammalian 
message (Macejak and Sarnow, 1991). IRES elements can 
be linked to heterologous open reading frames. Multiple 
open reading frames can be transcribed together, each Sepa 
rated by an IRES, creating polycistronic messages. By virtue 
of the IRES element, each open reading frame is accessible 
to ribosomes for efficient translation. Multiple genes can be 
efficiently expressed using a Single promoter/enhancer to 
transcribe a single message. 
Any heterologous open reading frame can be linked to 
IRES elements. This includes genes for Secreted proteins, 
multi-Subunit proteins, encoded by independent genes, intra 
cellular or memrbrane-bound proteins and Selectable mark 
erS. In this way, expression of Several proteins can be 
Simultaneously engineered into a cell with a single construct 
and a single Selectable marker. 
iv) Viral Vectors 
Another useful variation of the expression vector is the 
viral vector. The ability of certain viruses to enter cells via 
receptor-mediated endocytosis, to integrate into host cell 
genome and express viral genes Stably and efficiently have 
made them attractive candidates for the transfer of foreign 
genes into mammalian cells (Ridgeway, 1988; Nicolas and 
Rubenstein, 1988; Baichwal and Sugden, 1986; Temin, 
1986). The first viruses used as gene vectors were DNA 
viruses including the papovaviruses (simian virus 40, bovine 
papilloma virus, and polyoma) (Ridgeway, 1988, Baichwal 
and Sugden, 1986) and adenoviruses (Ridgeway, 1988; 
Baichwal and Sugden, 1986). These have a relatively low 
capacity for foreign DNA sequences and have a restricted 
host Spectrum. Furthermore, their oncogenic potential and 
cytopathic effects in permissive cells raise Safety concerns. 
They can accommodate only up to 8 kb of foreign genetic 
material but can be readily introduced in a variety of cell 
lines and laboratory animals (Nicolas and Rubenstein, 1988; 
Temin, 1986). 
One of the preferred methods for in vivo delivery involves 
the use of an adenovirus expression vector. "Adenovirus 
expression vector' is meant to include those constructs 
containing adenovirus Sequences Sufficient to (a) Support 
packaging of the construct and (b) to express a polynucle 
otide (sense or antisense) that has been cloned therein. In 
this context, expression does not require that the gene 
product be Synthesized. 
The expression vector comprises a genetically engineered 
form of adenovirus. Knowledge of the genetic organization 
of adenovirus, a 36 kb, linear, double-stranded DNA virus, 
allows substitution of large pieces of adenoviral DNA with 
foreign sequences up to 7 kb (Grunhaus and Horwitz, 1992). 
In contrast to retrovirus, the adenoviral infection of host 
cells does not result in chromosomal integration because 
adenoviral DNA can replicate in an episomal manner with 
out potential genotoxicity. Also, adenoviruses are structur 
ally stable, and no genome rearrangement has been detected 
after extensive amplification. Adenovirus can infect Virtually 
all epithelial cells regardless of their cell cycle Stage. So far, 
adenoviral infection appears to be linked only to mild 
disease Such as acute respiratory disease in humans. 
Adenovirus is particularly Suitable for use as a gene 
transfer vector because of its mid-sized genome, ease of 
manipulation, high titer, wide target cell range and high 
infectivity. Both ends of the viral genome contain 100-200 
base pair inverted repeats (ITRS), which are cis elements 
necessary for viral DNA replication and packaging. The 
early (E) and late (L) regions of the genome contain different 
transcription units that are divided by the onset of viral DNA 
replication. The E1 region (E1A and E1B) encodes proteins 
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responsible for the regulation of transcription of the viral 
genome and a few cellular genes. The expression of the E2 
region (E2A and E2B) results in the synthesis of the proteins 
for viral DNA replication. These proteins are involved in 
DNA replication, late gene expression and host cell shut-off 
(Renan, 1990). The products-of the late genes, including the 
majority of the viral capsid proteins, are expressed only after 
Significant processing of a single primary transcript issued 
by the major late promoter (MLP). The MLP, (located at 
16.8 m.u.) is particularly efficient during the late phase of 
infection, and all the mRNA's issued from this promoter 
possess a 5'-tripartite leader (TPL) sequence which makes 
them preferred mRNA's for translation. 
In a current System, recombinant adenovirus is generated 
from homologous recombination between shuttle vector and 
provirus vector. Due to the possible recombination between 
two proviral vectors, wild-type adenovirus may be generated 
from this process. Therefore, it is critical to isolate a single 
clone of virus from an individual plaque and examine its 
genomic Structure. 
Generation and propagation of the current adenovirus 
vectors, which are replication deficient, depend on a unique 
helper cell line, designated 293, which was transformed 
from human embryonic kidney cells by Ad5 DNA fragments 
and constitutively expresses E1 proteins (Graham et al., 
1977). Since the E3 region is dispensable from the aden 
ovirus genome (Jones and Shenk, 1978), the current aden 
ovirus vectors, with the help of 293 cells, carry foreign DNA 
in either the E1, the D3 or both regions (Graham and Prevec, 
1991). In nature, adenovirus can package approximately 
105% of the wild-type genome (Ghosh-Choudhury et al., 
1987), providing capacity for about 2 extra kb of DNA. 
Combined with the approximately 5.5 kb of DNA that is 
replaceable in the E1 and E3 regions, the maximum capacity 
of the current adenovirus vector is under 7.5 kb, or about 
15% of the total length of the vector. More than 80% of the 
adenovirus viral genome remains in the Vector backbone and 
is the Source of vector-borne cytotoxicity. Also, the replica 
tion deficiency of the E1-deleted virus is incomplete. For 
example, leakage of Viral gene expression has been observed 
with the currently available vectors at high multiplicities of 
infection (MOI) (Mulligan, 1993). 
Helper cell lines may be derived from human cells such 
as human embryonic kidney cells, muscle cells, hematopoi 
etic cells or other human embryonic mesenchymal or epi 
thelial cells. Alternatively, the helper cells may be derived 
from the cells of other mammalian Species that are permis 
Sive for human adenovirus. Such cells include, e.g., Vero 
cells or other monkey embryonic mesenchymal or epithelial 
cells. As stated above, the preferred helper cell line is 293. 
Recently, Racher et al. (1995) disclosed improved meth 
ods for culturing 293 cells and propagating adenovirus. In 
one format, natural cell aggregates are grown by inoculating 
individual cells into 1 liter Siliconized spinner flaskS 
(Techne, Cambridge, UK) containing 100-200 ml of 
medium. Following stirring at 40 rpm, the cell viability is 
estimated with trypan blue. In another format, Fibra-Cel 
microcarriers (Bibby Sterlin, Stone, UK) (5 g/l) is employed 
as follows. A cell inoculum, resuspended in 5 ml of medium, 
is added to the carrier (50 ml) in a 250 ml Erlenmeyer flask 
and left Stationary, with occasional agitation, for 1 to 4 h. 
The medium is then replaced with 50 ml of fresh medium 
and Shaking initiated. For virus production, cells are allowed 
to grow to about 80% confluence, after which time the 
medium is replaced (to 25% of the final volume) and 
adenovirus added at an MOI of 0.05. Cultures are left 
Stationary overnight, following which the Volume is 













Other than the requirement that the adenovirus vector be 
replication defective, or at least conditionally defective, the 
nature of the adenovirus vector is not believed to be crucial 
to the Successful practice of the invention. The adenovirus 
may be of any of the 42 different known serotypes or 
Subgroups A-F. Adenovirus type 5 of Subgroup C is the 
preferred Starting material in order to obtain the conditional 
replication-defective adenovirus vector for use in the present 
invention. This is because Adenovirus type 5 is a human 
adenovirus about which a great deal of biochemical and 
genetic information is known, and it has historically been 
used for most constructions employing adenovirus as a 
VectOr. 
AS Stated above, the typical vector according to the 
present invention is replication defective and will not have 
an adenovirus E1 region. Thus, it will be most convenient to 
introduce the polynucleotide encoding the gene of interest at 
the position from which the E1-coding Sequences have been 
removed. However, the position of insertion of the construct 
within the adenovirus Sequences is not critical to the inven 
tion. The polynucleotide encoding the gene of interest also 
may be inserted in lieu of the deleted E3 region in E3 
replacement vectors as described by Karlsson et al., (1986) 
or in the E4 region where a helper cell line or helper virus 
complements the E4 defect. 
Adenovirus is easy to grow and manipulate and exhibits 
broad host range in vitro and in Vivo. This group of Viruses 
can be obtained in high titers, e.g., 10°-10' plaque-forming 
units per ml, and they are highly infective. The life cycle of 
adenovirus does not require integration into the host cell 
genome. The foreign genes delivered by adenovirus vectors 
are episomal and, therefore, have low genotoxicity to host 
cells. No side effects have been reported in Studies of 
vaccination with wild-type adenovirus (Couch et al., 1963; 
Top et al., 1971), demonstrating their Safety and therapeutic 
potential as in Vivo gene transfer vectors. 
Adenovirus vectors have been used in eukaryotic gene 
expression (Levrero et al., 1991; Gomez-Foix et al., 1992) 
and vaccine development (Grunhaus and Horwitz, 1992; 
Graham and Prevec, 1992). Recently, animal studies Sug 
gested that recombinant adenovirus could be used for gene 
therapy (Stratford-Perricaudet and Perricaudet, 1991; 
Stratford-Perricaudet et al., 1990; Rich et al., 1993). Studies 
in administering recombinant adenovirus to different tissues 
include trachea instillation (Rosenfeld et al., 1991; Rosen 
feld et al., 1992), muscle injection (Ragot et al., 1993), 
peripheral intravenous injections (Herz and Gerard, 1993) 
and Stereotactic inoculation into the brain (Le Gal La Salle 
et al., 1993). 
The retroviruses are a group of Single-Stranded RNA 
viruses characterized by an ability to convert their RNA to 
double-stranded DNA in infected cells by a process of 
reverse-transcription (Coffin, 1990). The resulting DNA then 
Stably integrates into cellular chromosomes as a provirus 
and directs Synthesis of viral proteins. The integration results 
in the retention of the viral gene Sequences in the recipient 
cell and its descendants. The retroviral genome contains 
three genes, gag, pol, and enV that code for capsid proteins, 
polymerase enzyme, and envelope components, respec 
tively. A sequence found upstream from the gag gene 
contains a signal for packaging of the genome into Virions. 
Two long terminal repeat (LTR) sequences are present at the 
5' and 3' ends of the viral genome. These contain Strong 
promoter and enhancer Sequences and are also required for 
integration in the host cell genome (Coffin, 1990). 
In order to construct a retroviral vector, a nucleic acid 
encoding a gene of interest is inserted into the Viral genorne 
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in the place of certain viral Sequences to produce a virus that 
is replication-defective. In order to produce virions, a pack 
aging cell line containing the gag, pol, and enV genes but 
without the LTR and packaging components is constructed 
(Mann et al; 1983). When a recombinant plasmid containing 
a cDNA, together with the retroviral LTR and packaging 
Sequences is introduced into this cell line (by calcium 
phosphate precipitation for example), the packaging 
sequence allows the RNA transcript of the recombinant 
plasmid to be packaged into viral particles, which are then 
Secreted into the culture media (Nicolas and Rubenstein, 
1988; Temin, 1986; Mann et al., 1983). The media contain 
ing the recombinant retroviruses is then collected, optionally 
concentrated, and used for gene transfer. Retroviral vectors 
are able to infect a broad variety of cell types. However, 
integration and Stable expression require the division of host 
cells (Paskind et al., 1975). 
A novel approach designed to allow Specific targeting of 
retrovirus vectors was recently developed based on the 
chemical modification of a retrovirus by the chemical addi 
tion of lactose residues to the viral envelope. This modifi 
cation could permit the Specific infection of hepatocytes via 
Sialoglycoprotein receptors. 
A different approach to targeting of recombinant retrovi 
ruses was designed in which biotinylated antibodies against 
a retroviral envelope protein and against a Specific cell 
receptor were used. The antibodies were coupled via the 
biotin components by using streptavidin (Roux et al., 1989). 
Using antibodies against major histocompatibility complex 
class I and class II antigens, they demonstrated the infection 
of a variety of human cells that bore those Surface antigens 
with an ecotropic virus in vitro (Roux et al., 1989). 
There are certain limitations to the use of retrovirus 
vectors in all aspects of the present invention. For example, 
retrovirus vectors usually integrate into random Sites in the 
cell genome. This can lead to insertional mutagenesis 
through the interruption of host genes or through the inser 
tion of Viral regulatory Sequences that can interfere with the 
function of flanking genes (Varmus et al., 1981). Another 
concern with the use of defective retrovirus vectors is the 
potential appearance of wild-type replication-competent 
Virus in the packaging cells. This can result from recombi 
nation events in which the intact-Sequence from the recom 
binant virus inserts upstream from the gag, pol, env 
Sequence integrated in the host cell genome. However, new 
packaging cell lines are now available that should greatly 
decrease the likelihood of recombination (Markowitz et al., 
1988; Hersdorffer et al., 1990). 
Other viral vectors may be employed as expression con 
Structs in the present invention. Vectors derived from Viruses 
such as vaccinia virus (Ridgeway, 1988; Baichwal and 
Sugden, 1986; Coupar et al., 1988) adeno-associated virus 
(AAV) (Ridgeway, 1988; Baichwal and Sugden, 1986; Her 
monat and Muzycska, 1984) and herpesviruses may be 
employed. They offer several attractive features for various 
mammalian cells (Friedmann, 1989; Ridgeway, 1988; 
Bajchwal and Sugden, 1986; Coupar et al., 1988; Horwich 
et al., 1990). 
With the recent recognition of defective hepatitis B 
Viruses, new insight was gained into the Structure-function 
relationship of different viral Sequences. In vitro Studies 
showed that the virus could retain the ability for helper 
dependent packaging and reverse transcription despite the 
deletion of up to 80% of its genome (Horwich et al., 1990). 
This Suggested that large portions of the genome could be 
replaced with foreign genetic material. The hepatotropism 











properties for liver-directed gene transfer. Chang et al., 
recently introduced the chloramphenicol acetyltransferase 
(CAT) gene into duck hepatitis B virus genome in the place 
of the polymerase, Surface, and pre-Surface coding 
Sequences. It was cotransfected with wild-type virus into an 
avian hepatoma cell line. Culture media containing high 
titers of the recombinant Virus were used to infect primary 
duckling hepatocytes. Stable CAT gene expression was 
detected for at least 24 days after transfection (Chang et al., 
1991). 
D. Methods of Transforming Cells 
In order to effect expression of Sense or antisense gene 
constructs, the expression construct must be delivered into a 
cell. This delivery may be accomplished in Vitro, as in 
laboratory procedures for transforming cells lines, or in vivo 
or eX Vivo, as in the treatment of certain disease States. One 
mechanism for delivery is via viral infection where the 
expression construct is encapsidated in an infectious viral 
particle. 
Several non-viral methods for the transfer of expression 
constructs into cultured mammalian cells also are contem 
plated by the present invention. These include calcium 
phosphate precipitation (Graham and Van Der Eb, 1973; 
Chen and Okayama, 1987; Rippe et al., 1990) DEAE 
dextran (Gopal, 1985), electroporation (Tur-Kaspa et al., 
1986; Potter et al., 1984), direct microinjection (Harland and 
Weintraub, 1985), DNA-loaded liposomes (Nicolau and 
Sene, 1982; Fraley et al., 1979) and lipofectamine-DNA 
complexes, cell Sonication (Fechheimer et al., 1987), gene 
bombardment using high Velocity microprojectiles (Yang et 
al., 1990), and receptor-mediated transfection (Wu and Wu, 
1987; Wu and Wu, 1988). Some of these techniques may be 
successfully adapted for in vivo or ex vivo use. RNA 
compositions also may be delivered to cells using these 
methods. RNA, for example, a pool of in vitro synthesized 
mRNA may be complexed similarly to the DNA complexes 
described above, for delivery into cells. 
Once the expression construct has been delivered into the 
cell the nucleic acid encoding the gene of interest may be 
positioned and expressed at different Sites. In certain 
embodiments, the nucleic acid encoding the gene may be 
Stably integrated into the genome of the cell. This integration 
may be in the cognate location and orientation via homolo 
gous recombination (gene replacement) or it may be inte 
grated in a random, non-specific location (gene 
augmentation). In yet futher embodiments, the nucleic acid 
may be stably maintained in the cell as a separate, episomal 
Segment of DNA. Such nucleic acid Segments or “episomes” 
encode Sequences Sufficient to permit maintenance and 
replication independent of or in Synchronization with the 
host cell cycle. How the expression construct is delivered to 
a cell and where in the cell the nucleic acid remains is 
dependent on the type of expression construct employed. 
The introduction of DNA, mRNA or protein into cells by 
microinjection can be used to Screen for molecules capable 
of imparting novel characteristics to the injected cell, or to 
rescue defects in the injected cell. Microinjection is per 
formed by puncturing the cell with an injection needle or 
pipette containing the DNA, mRNA or protein of interest, 
and forcing a portion of these contents into the cell by 
applying positive pressure. In Xenopus embryos the most 
commonly introduced material is in Vitro synthesized 
mRNA (Vize etal., 1991), but expression plasmids and even 
antibodies also may be used. The basic experiment is 
performed by: 
1. Performing an in vitro fertilization of Xenopus eggs, 
2. removing the jelly coat of the fertilized embryos, 
US 6,479.285 B1 
17 
3. culture of embryoS in a Simple Saline Solution until the 
required Stage. This is usually Somewhere between the 
2 cell stage (approx. 80 minutes post-fertilization) and 
the 64-cell Stage; 
4. embrydos are placed in a solution of Ficol then 
microinjected with the molecule(s) of interest 
5. embryos are allowed to recover in Ficoll solution for a 
number of hours then returned to simple saline buffer 
6. embryos are raised to the Stage of interest then exam 
ined for an effect of the injected molecules by analyzing 
gene expression in repose to the introduced molecule(s) 
or by analyzing the morphology of the embryo in 
response to the introduced molecule(s). 
In certain embodiments, the inventors contemplate intro 
ducing a molecule that alters the developmental fate of an 
embryonic cell. The cells at the animal pole (the top, darkly 
pigmented portion) of Xenopus embryos will normally form 
the epidermis and neural tissue of the tadpole, and the frog 
which will develop from the tadpole. The animal pole can be 
cut off from an early Stage embryo and cultured in a simple 
Saline Solution in isolation from the remainder of the 
embryo. Under Such circumstances the animal pole will 
differentiate into a ball of epidermal cells. The cells have not 
yet received the necessary Signals from the bottom half of 
the embryos which instruct a portion of the animal pole cells 
to form the nervous System. Such animal pole explants do 
not form any mesodermal tissue, Such as muscle or noto 
chord. The animal pole cells are naive embryonic cells: they 
are not yet differentiated but have the potential to form many 
different types of cell. 
The ability of a gene or gene product to encode a specific 
pathway of differentiation can be tested by introducing the 
gene into the animal pole of an early embryo. If the animal 
pole of Such an embryo is then removed and cultured in 
isolation the ability of the injected molecule to alter cell fate 
from epidermal (the default) can be examined. For example, 
the Brachyury gene plays a key role in the development of 
meSodermal cells, including muscle. If an mRNA encoding 
Brachury is injected into the animal pole of early Xenopus 
embryos, the embryos are grown to blastula Stage, and the 
animal pole is removed and cultured in isolation, the pole 
cells will differentiate into both epidermal cells (the default) 
and mesodermal cells including muscle cells. The differen 
tiation of muscle can be detected by assaying for the 
expression of muscle Specific gene expression or by histol 
ogy to directly visualize the formation of embryonic muscle 
blocks, or somites (O'Reilly et al., 1995). 
Pools of mRNA from embryonic tissue also can be 
microinjected into the animal pole and induce the formation 
of cells which would not normally form in isolated animal 
cells. Examples include ovary mRNA and mRNA from 
Xenopus cultured cell lines which leads to the formation of 
mesodermal cells (Woodland and Jones, 1987). Although 
Such complex pools have not been fractionated to yield 
Specific gene products with mesoderm inducing activities 
(these mesoderm inducing molecules were identified by 
other means making the Screen redundant) Such a screen is 
very feasible. 
In other embodiments, the inventors contemplate rescue 
of an embryonic deficiency by microinjection of mRNA. 
Defects in embryos can be rescued by Supplying the defec 
tive embryo with a gene product capable of providing, or 
compensating for, factors missing in the embryo. A com 
monly used System in Xenopus is the generation of Ventral 
ized embryos by irradiating early embryos with ultraviolet 
light. The UV light disrupts cytoplasmic rearrangements 











genes required for the development of dorsal cell types. 
Such embryoS lack dorsal Structures Such as a head, noto 
chord and muscle. 
If UV-irradiated embryos are microinjected with an 
mRNA encoding a gene capable of directing cells to form 
dorsal Structures, the injected mRNA can rescue the defi 
ciency in Such structures and result in normal development. 
Single cloned gene products with rescuing activity work 
under Such circumstances, for example Xwnt-8, (Sokol et 
al., 1991, Smith and Harland, 1991), as do complex mixtures 
of embryonic mRNA enriched for genes expressed in dorsal 
tissues (Smith and Harland 1992). When complex mixtures 
of mRNA with UV rescuing activity were identified the 
fractionation of such mRNA pools eventually led to the 
identification of novel gene products involved in Specifying 
dorsal development (Smith and Harland, 1991, 1992). 
In Specific embodiments, the inventors contemplate using 
a combination of these approaches. The inventors contem 
plate introduction of a single mRNA (mutant p53) to induce 
a defect plus a pool of mixed mRNAS which may be able to 
rescue the defect. By Screening hundreds of Such complex 
pools the inventors can identify gene products capable of 
overriding the requirement for p53 in differentiation. Once 
Such active pools are identified, they can be broken down 
into subpools which can then be retested. These will once 
again be broken down until Single gene products is identi 
fied. 
In yet another embodiment of the invention, the expres 
Sion construct may simply consist of naked recombinant 
DNA or plasmids. Transfer of the construct may be per 
formed by any of the methods mentioned above which 
physically or chemically permeabilize the cell membrane. 
This is particularly applicable for transfer in vitro but it may 
be applied to in vivo use as well. Dubensky et al. (1984) 
successfully injected polyomavirus DNA in the form of 
calcium phosphate precipitates into liver and Spleen of adult 
and newborn mice demonstrating active viral replication and 
acute infection. Benvenisty and Neshif (1986) also demon 
Strated that direct intraperitoneal injection of calcium 
phosphate-precipitated plasmids results in expression of the 
transfected genes. It is envisioned that DNA encoding a gene 
of interest also may be transferred in a similar manner in 
Vivo and express the gene product. 
In still another embodiment of the invention for transfer 
ring a naked DNA expression construct into cells may 
involve particle bombardment. This method depends on the 
ability to accelerate DNA-coated microprojectiles to a high 
Velocity allowing them to pierce cell membranes and enter 
cells without killing them (Klein et al., 1987). Several 
devices for accelerating Small particles have been devel 
oped. One Such device relies on a high Voltage discharge to 
generate an electrical current, which in turn provides the 
motive force (Yang et al., 1990). The microprojectiles used 
have consisted of biologically inert Substances Such as 
tungsten or gold beads. 
Selected organs including the liver, Skin, and muscle 
tissue of rats and mice have been bombarded in vivo (Yang 
et al., 1990; Zelenin et al., 1991). This may require surgical 
exposure of the tissue or cells, to eliminate any intervening 
tissue between the gun and the target organ, i.e., ex vivo 
treatment. Again, DNA encoding a particular gene may be 
delivered via this method and still be incorporated by the 
present invention. 
In a further embodiment of the invention, the expression 
construct may be entrapped in a liposome. Liposomes are 
vesicular structures characterized by a phospholipid bilayer 
membrane and an inner aqueous medium. Multilamellar 
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liposomes have multiple lipid layerS Separated by aqueous 
medium. They form Spontaneously when phospholipids are 
Suspended in an excess of aqueous Solution. The lipid 
components undergo Self-rearrangement before the forma 
tion of closed Structures and entrap water and dissolved 
solutes between the lipid bilayers (Ghosh and Bachhawat, 
1991). Also contemplated are lipofectamine-DNA com 
plexes. 
Liposome-mediated nucleic acid delivery and expression 
of foreign DNA in vitro has been very successful. Wong et 
al., (1980) demonstrated the feasibility of liposome 
mediated delivery and expression of foreign DNA in cul 
tured chick embryo, HeLa and hepatoma cells. Nicolau et 
al., (1987) accomplished Successful liposome-mediated 
gene transfer in rats after intravenous injection. 
In certain embodiments of the invention, the lipoSome 
may be complexed with a hemagglutinating virus (HVJ). 
This has been shown to facilitate fusion with the cell 
membrane and promote cell entry of liposome-encapsulated 
DNA (Kaneda et al., 1989). In other embodiments, the 
lipoSome may be complexed or employed in conjunction 
with nuclear non-histone chromosomal proteins (HMG-1) 
(Kato et al., 1991). In yet further embodiments, the liposome 
may be complexed or employed in conjunction with both 
HVJ and HMG-1. In that such expression constructs have 
been Successfully employed in transfer and expression of 
nucleic acid in Vitro and in Vivo, then they are applicable for 
the present invention. Where a bacterial promoter is 
employed in the DNA construct, it also will be desirable to 
include within the liposome an appropriate bacterial poly 
CSC. 
Other expression constructs which can be employed to 
deliver a nucleic acid encoding a particular gene into cells 
are receptor-mediated delivery vehicles. These take advan 
tage of the Selective uptake of macromolecules by receptor 
mediated endocytosis in almost all eukaryotic cells. Because 
of the cell type-specific distribution of various receptors, the 
delivery can be highly specific (Wu and Wu, 1993). 
Receptor-mediated gene targeting vehicles generally con 
sist of two components: a cell receptor-specific ligand and a 
DNA-binding agent. Several ligands have been used for 
receptor-mediated gene transfer. The most extensively char 
acterized ligands are asialoorosomucoid (ASOR) (Wu and 
Wu, 1987) and transferrin (Wagner et al., 1990). Recently, a 
Synthetic neoglycoprotein, which recognizes the same 
receptor as ASOR, has been used as a gene delivery vehicle 
(Ferkol et al., 1993; Perales et al., 1994) and epidermal 
growth factor (EGF) has also been used to deliver genes to 
squamous carcinoma cells (Myers, EPO 0273085). 
In other embodiments, the delivery vehicle may comprise 
a ligand and a liposome. For example, Nicolau et al., (1987) 
employed lactosyl-ceramide, a galactose-terminal 
asialganglioside, incorporated into liposomes and observed 
an increase in the uptake of the insulin gene by hepatocytes. 
Thus, it is feasible that a nucleic acid encoding a particular 
gene also may be specifically delivered into a cell type Such 
as lung, epithelial or tumor cells, by any number of receptor 
ligand Systems with or without liposomes. For example, 
epidermal growth factor (EGF) may be used as the receptor 
for mediated delivery of a nucleic acid encoding a gene in 
many tumor cells that exhibit upregulation of EGF receptor. 
Mannose can be used to target the mannose receptor on liver 
cells. Also, antibodies to CD5 (CLL), CD22 (lymphoma), 
CD25 (T-cell leukemia) and MAA (melanoma) can similarly 
be used as targeting moieties. 
E. Assay Formats According to the Present Invention 
The present invention involves the monitoring of p53, as 











for the ability to overcome blocks in p53 function. A variety 
of different formats are available, utilizing both in vitro and 
in Vivo approaches. These are discussed, generally, below. 
i) In vitro 
In vitro assays have a distinct advantage over in vivo 
assays in that the requirements for cell culture are leSS 
Stringent, and often less expensive, than for in Vivo Systems. 
However, they suffer, in some contexts from the fact that 
whole organism models are, by their very nature, more 
reflective of the developmental patterns Seen in nature. 
Nonetheless, in vitro models are powerful tools, especially 
when the Screening involves large numbers of compounds. 
In a first embodiment, the present invention encompasses 
the use of pluriopotent embryonic cells in various culture 
assays. These cells may be obtained from the blastocoel of 
Virtually any organism by needle aspiration. Culture of these 
undifferentiated, totipotent cells is performed in the presence 
of a factor that will prevent their differentiation. An example 
of such a factor is LIF or alternatively by culturing on 
embryonic feeder cells which provides the LIF. In the 
presence of LIF, embryonic cells remain totipotent and 
undifferentiated. Removal of LIF from the culture permits 
differentiation. 
Other culture parameters for embryonic Stem cells include 
culture in methylcellulose, fetal calf Serum and 
monothioglycerol, B-mercaptoethanol or other reducing 
agent. 
Depending on other culture conditions, the type of dif 
ferentiation will vary. For example, ES cells are maintained 
in LIF or embryonic feeder cells on culture grade plastic. To 
induce differentiation they are palced on bacterial grade 
plastic in a medium containing fetal calf Serum, and usually 
a reducing agent for example BME or MTG. The FCS is 
required for differnetiation to occur. Often, this differentia 
tion is performed in Semi-Solid media conatining methyl 
cellulose. Variations of these culture conditions which give 
rise to other cell types are usually variations in tissue 
culturgrade palstic, methylcellulose Semi-Solid media, FCS, 
reducing agents and other chemicals and growth factors. For 
example, culture with retinoic acid gives rise to neural cells. 
Culture with erythropoietin causes hematopoietic cells to 
form. Culture with interleukin 3 causes formation of 
macrophages, neutrophils and mast cells. Culture with inter 
leukin 3, interleukin 1, and macrophage colony Stimulating 
factor or granulocyte-macrophage colony Stimulating factor 
results in the formation of macrophages. Culture with bone 
morphogenetic protein 4 gives rise to hematopoietic cells. 
Once the culture System is established, one may bring the 
candidate test Substance into contact with the cells. At Such 
a time, the differentiation-inhibiting factor is removed, and 
the effects of the candidate Substance on differentiation are 
observed. Proper controls include culturing cells in the 
absence of the factor, but without the candidate Substance. 
Dose range and escalation Studies also are contemplated. 
Depending on the nature of the candidate Substance, the 
contacting may comprise merely coculturing the cells with 
the Substance. Other Substances should be delivered to the 
inside of the cell. This can be accomplished by microinjec 
tion or, in the case of nucleic acids, by the methods Set forth 
above. 
Sufficient culture time is required following the contact 
ing of the candidate Substance with the embryonic cells. 
Depending on the cell, this time will vary considerably, but 
the appropriate time may easily be ascertained by removing 
the differentiation-inhibiting factor from untreated cells and 
determining the period need for differentiation of these cells 
into the expected cell type. For murine cells, the typical time 
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is approximately 10 days. Amphibian (Xenophus) cells 
require, generally, about 2 days, and insect (Drosophila) 
cells differentiate in about 12 days. 
ii) In vivo 
An alternative to in vitro assays is an in vivo. While more 
complex and expensive than in vitro assays, in Vivo assays 
may more accurately reflect the natural State, and thereby 
provide more accurate information, at least with respect to 
Some properties. A number of different assays are contem 
plated. The examples discussed below are not intended to be 
all inclusive of the Systems which may be utilized, as 
Virtually any biological System can be adapated for the 
purposes of the present invention. 
1. Xenopus 
In one embodiment, the Xenopus laevis System is 
employed. AS indicated above, Xenopus p53 is very similar 
to human p53, and Xenopus embryos contain a ubiquitous 
maternal stockpile of p53 mRNA and protein. In order to 
inactivate the endogenous p53, mRNA encoding a dominant 
negative form of p53 can be microinjected into a single or 
multiple blastomere(s). Preferred is injection into the 32-cell 
Stage blastomere, into presumptive mesodermal tissue. 
However, other Stages of development also may be 
employed, for example, 8, 16, 32, 64 or 128 cell Stages will 
work at differing efficiencies. A particular advantage of c 
lturing Xenopus embryoS is that Such cultures are markedly 
leSS expensive than culturing mammalian cells in vitro. 
Alternatively, one can inactive the resident p53 by 
providing, to the blastomere cell, a double minute-2 onco 
protein. This molecule binds to the transcriptional activation 
domain of p53 and inactivates its function. Again, mRNA 
encoding the double minute-2 molecule is injected into the 
blastomere cell, and expression of the corresponding 
polypeptide will block p53 function. 
Another advantageous embodiment includes the injection 
into cells of a marker gene. Such a gene permits tracing of 
the lineage of injected cells in later development. Examples 
include B-galactosidase, green fluorescent protein and 
luciferase. When embryoS reach tadpole Stage, tissues can be 
fixed and Stained, for example, for B-galactosidase activity 
using an appropriate chromogenic Substrate. 
Histological analysis of tissues injected with either domi 
nant negative p53 mutants or the double minute-2 oncopro 
tein show cell masses that resemble tumors and also are 
reminiscent of undifferentiated embryonic cells. Abnormal 
nuclear morphologies also were observed. Histologically, 
these tissues are considered to be blastomas. 
According to the present invention, it is contemplated that 
this model for tumor development can be used to Screen for 
agents that inhibit p53-related tumor development. In vari 
ous embodiments, candidate inhibitors are contacted with 
the engineered cells. Depending on the candidate agent, the 
route of delivery will vary. For example, merely contacting 
the cell with an organo-pharmnaceutical may be Sufficient, 
whereas the preferred mode of contacting for nucleic acids, 
both RNA's and DNA's, is to transfer the nucleic acid into 
the cell. This can be accomplished by any of the techniques 
mentioned above. 
It then remains only to monitor the development of the 
ensuing tissues, which can be traced by use of a marker gene 
like B-galactosidase, and determine their histology as com 
pared to tissues that develop normally and those that develop 
without the benefit of the developmental control of p53. 
Typical methods of monitoring include histologic analysis 
(microscopic, immunohistochemistry), protein analysis 
(Western blot, SDS-PAGE, 2D PAGE), TUNEL analysis. 











contemplated. These markers can be measured as expression 
of genes or proteins expressed in differentiated cells. Gene 
expression can be assayed using techniques well known to 
those of skill in the art, for example, by Northern Blotting, 
RNase protection assays, RT-PCR or a variety of other 
techniques. Proteins expressed can be assayed Visually (e.g. 
the production of hemoglobin in differentiating ES cells) or 
by the other assays listed above. 
2. Drosophila 
Another System that may advantageously be employed in 
an in Vivo context is Drosophila melanogaster. Drosophila 
genetics have been extensively Studied and, thus, provide a 
fruitful Starting point for analysis. One embodiment employs 
use of tissue specific promoters in Drosophila to drive the 
expression of a dominant negative p53 gene or a double 
minute-2 gene, thereby knocking out p53 functions in these 
cells. Because only certain tissues will be targeted, one can 
monitor the development, or lack thereof, of these tissues. 
Preferably, the tissues to be targeted are non-essential, i.e., 
the fly can develop and live, at least temporarily, without 
them. One example of Such a promoter is the eyeless 
promoter. This regulatory element is specifically turned on 
in tissues destined for eye development. The activation of 
this promoter, when linked to a mutant p53 or double 
minute-2 gene, will result in the absence of eye tissue 
formation. This is a non-lethal defect that is easily observed. 
Other promoters that may prove useful include but are not 
limited to gala responsive promoter, heat Shock promoter 
and hairy promoter. 
AS discussed above, the engineering of blastomeres pri 
marily relies on transfer of gene (mutant p53, double 
minute-2) to cells, with or without marker genes. Once 
transformed in this manner, the developmental pattern of the 
cells will be disrupted by virtue of the developmentally 
regulated expression of the blocking gene. In the case of 
eyeless, the absence of eye development will indicate that 
the blocking gene is expressed and operating. Provision of 
a candidate inhibitor Substance that is Sufficient to override 
the block well permit eye development. 
3. Mouse 
Mice were the first transgenic mammals and this System 
remains one of the best tested Systems for gene transfer into 
developing embryos. This System is more complex than the 
amphibian and insect Systems described above, but the large 
amount of work that has been done provides a very high 
level of expertise in manipulating murine embryonic cells. 
Essentially, mouse embryo cells may be manipulated as 
described above. 
Another option with this System in the generation of 
chimeric mice having both p53-blocked and unblocked 
cells. In some tissues the lack of p53 ultimately leads to 
death of the organism, but the present invention is useful in 
that chimeric mice may be generated that house lethally 
defective cells. Pluripotent stems cells can be removed from 
blastocysts and cultured in the presence of LIF to maintain 
totipotency. Once engineered to establish a p53 block (as 
discussed above), the cells can be introduced into a blasto 
coel. Implantation of the blastocyst into a foster mother, 
followed by gestation, results in a chimeric animal that has 
embryonic stem cells with both blocked an unblocked p53 
differentiation patterns. Such animals may then provide in 
vivo models and be examined for abnormalities develop 
ment arising from p53 abrogation. 
Thus a transgenic mouse expressing mutant p53 can be 
generated and tested for its developmental abilities. Such an 
animal may be used to test the effectiveness of compounds 
isolated from other Screens or for Screening new compounds 
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useful in blocking p53-related defects in cellular differen 
tiation. The transgenic mouse can be generated by direct 
microinjection of DNA or mRNA encoding mutant p53, or 
by introducing ES cells expressing mutant p53 into 
embryos, then testing the compounds directly on these 
embryos following transplantation. 
F. Candidate Substances 
According to the present invention, one may Screen any 
kind of candidate Substance for activity in the assays 
described above. Although drug design principles may be 
employed, one of the advantages of the present invention is 
that large numbers of compounds may be Screened 
i) Pharmaceuticals 
Any classic pharmaceutical may be tested according to 
the present invention. Useful compounds in this regard will 
include those compounds, and compounds related thereto, 
that are known to affect cellular development and tumori 
genesis. Many classic pharmaceuticals are derived from 
naturally occurring compounds, and also may include frag 
ments or parts of naturally-occurring compounds, or may be 
only found as active combinations of known compounds 
which are otherwise inactive. 
Particularly fruitful Sources for pharmaceuticals include 
bacteria, fungi, plant Sources, including leaves and bark, and 
marine Samples may be assayed as candidates for the 
presence of potentially useful pharmaceutical agents. It will 
be understood that the pharmaceutical agents to be Screened 
could also be derived or Synthesized from chemical com 
positions or man-made compounds. 
ii) Expression Libraries 
Expression libraries, also known as cDNA libraries, com 
prises complementary DNA copies of mRNA's from a 
Selected cell or tissue. These libraries represent the genetic 
information that is transcribed in the cells. The cDNAs are 
cloned into plasmids Such that they are positioned under the 
control of regulatory Signals that permit the transcription and 
translation of the mRNA produced therefrom. 
In one embodiment, expression libraries may be used in 
a random fashion. These libraries are contacted with cells 
have a p53-related block in differentiation. After monitoring 
the effects that the library has on individual cells, cells which 
exhibit the desired characteristics can be isolated, and DNA 
therein analyzed. In this manner, the expression plasmid can 
be identified and the gene responsible for the desired char 
acteristic Sequenced. 
In other embodiments, candidate members of an expres 
sion library may be utilized selectively, thereby obviating 
the need for later identification. This approach is more time 
consuming and permits only testing of Selected clones. This 
generally requires that Some additional criteria be used to 
narrow the candidate clones or genes. 
iii) mRNA Pools 
Messenger RNA's encode various proteins within a cell. 
It is possible to isolate mRNA's that are homogenous, or 
Substantially homogeneous and use these molecules in 
"gene' transfer experiments, as discussed above. For 
example, it is possible to generate mRNA's in cell free 
Systems using DNA's with the appropriate regulatory Sig 
nals as the template. Large amounts of homogeneous RNA 
can be produced in this fashion. 
Another approach to the production of mRNAs is to 
isolate whole cell or poly-ARNA's from tissues which have 
mRNA profiles that are predominated by a single species. 
This Single Species can be further purified in order to 
minimize the amount and number of contaminating minor 
species. Methods for isolating and handling mRNA's are 












iv) Small Molecule Libraries 
Small molecule libraries include both peptides and orga 
nochemicals. These compounds generally are generated in 
an automated fashion. For example, peptides may be Syn 
thesized to Substitute all possible variations at a single 
position. Series of peptides Substituting for each residue in 
a peptide permit “Scanning” of peptides for active sites. 
Similarly, organic molecules utilize Substitution of various 
R-groups with Structurally similar, but distinct, chemical 
units, Such as alkyl, aryl, alkenyl, etc. Many Such libraries 
are commercially available. 
G. Mutagenesis 
In a variation on the assays described above, another 
embodiment of the present invention involves the use of 
engineered embryonic cells to Screen for molecules that are 
involved with p53 and its function as a regulator of differ 
entiation. Basically, the initial Steps are as described 
above-obtaining an undifferentiated embryonic cell and 
blocking the function of p53 therein. Rather than attempting 
to overcome the block by Virtue of a drug, nucleic acid or 
protein, the engineered embryonic cell is mutagenized, for 
example, with radiation or a chemical DNA damaging agent. 
If the mutagenesis effects a change that results in the 
differentiation of the previously blocked cell, identification 
of the mutation should reveal a gene or regulatory Sequence 
that interacts with p53 or plays a role in a p53-related 
proceSS. 
Identification of the mutagenized gene involves Segregat 
ing the trait by means of breeding. Briefly, the mutagensis 
can be performed using chemical mutagens, irradiation and 
by P-element mediated mutagenesis to generate insertional 
mutants (Bingham et al., 1982, Cooley et al., 1988). 
Once mutations, which can either enhance or Suppress the 
developmental defect caused by expression of mutant p53, 
have been generated, they can be characterized using Stan 
dard genetic methods. Firstly, the position of the mutation 
which genetically interacts with mutant p53 gene will be 
mapped by determining with which genetic markers it 
co-Segregates. Meiotic recombination frequencies will then 
be used to map the genetic position of the mutation within 
the identified chromosome. Once the position of the muta 
tion has been refined candidate genes will be identified, if 
possible, from the detailed genetic and DNA data bases 
available on Drosophila. If known genes or mutations map 
to the identified region, these will be obtained from the 
laboratories which identified them. If candidate genes or 
mutants can be obtained from other laboratories, these will 
be tested in genetic crosses to determine if they correspond 
to the identified mutation. If the mutations map in regions 
containing no previously identified genes or mutations the 
region will be cloned and analyzed in order to identify the 
responsible genes. 
Cloning of the interacting mutants can be done in a 
number of ways. If the mutations have a phenotype in the 
absence of the mutant p53 P-element cloning can be 
achieved via a P-element mediated mutagenesis Screen, 
whereby the transposition of endogenous P-elements is used 
to disrupt the genome via insertional mutagenesis (Cooley et 
al., 1988). If a P-element insertion in trans to the p53 
interacting mutation generates the same phenotype as the 
interacting mutation in trans to itself, the insertion site is 
probably within the gene being Sought. A genomic library 
can be made from these flies and the P-element DNA 
Sequences used to isolated genomic fragments adjacent to 
the insertion Site. If the mutations only generate a phenotype 
in the presence of the mutant p53 P-element the analysis will 
be more complex. In this instance fine genetic mapping 
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followed by chromosome walking will be required to iden 
tify the responsible gene. Chromosome walking is achieved 
by making a stepwise progression through a genomic library 
using the extreme end of one clone to identify overlapping 
clones which correspond to Sequences further along the 
chomosome. The extreme end of this new clone is then used 
to identify even more distant Sequences, and So on. 
Two classes of mutations can be identified in a Screen 
Such as the one described. Mutations which rescue 
(Suppress) the block to differentiation imposed by mutant 
p53, and mutations which enhance the block to differentia 
tion. Of course, mutations in the introduced P-element 
disrupting the introduced p53 gene will also be generated, 
but these will be detected and will be discarded from the 
screen. Mutations which enhance the mutant p53 mediated 
block to differentiation probably act with p53. during the 
normal differentiation process, and mutations inactivating 
Such cofactors will contribute to the inhibition of differen 
tiation. In this instance the mutations will be loSS-of 
function mutants, whereby the mutation has inactivated an 
interacting gene. Such loSS-of-function muations may well 
have a developmental phenotype when in trans to 
themselves, even in the absense of the mutant p53 
P-element, which will make their genetic and molecular 
characterization much more Straightforward. Mutations 
which suppress the mutant p53 phenotype will probably be 
caused by gain-of-function (neomorphic) mutations. Such 
mutations either increase the level or activity of a gene or 
gene product in Such a way as to over-ride the ability of 
mutant p53 to SuppreSS this activity. Gain-of-function muta 
tions also can impart novel activities upon a gene or gene 
product. Such mutants may or may not require the mutant 
p53 gene in order to cause a developmental defect. 
Examples of genes which could be identified by such 
Screening methods described above include mdm-2 null 
mice which die very early in development, and p53 null 
mice which survive. Mdm-2 null mice develop normally in 
a p53 null genetic background. In this example the p53 
mutation Suppresses, or negates, the requirement for mdm-2 
activity. A mutagenesis Study of mdm-2 null mice would 
have identified the p53 gene. In the examples proposed 
herein above the opposite approach is being taken: generate 
a p53 null phenotype, then Screen for interacting genes. 
H. EXAMPLES 
The following examples are included to demonstrate 
preferred embodiments of the invention. It should be appre 
ciated by those of skill in the art that the techniques 
disclosed in the examples which follow represent techniques 
discovered by the inventor to function well in the practice of 
the invention, and thus can be considered to constitute 
preferred modes for its practice. However, those of skill in 
the art should, in light of the present disclosure, appreciate 
that many changes can be made in the Specific embodiments 
which are disclosed and still obtain a like or similar result 
without departing from the Spirit and Scope of the invention. 
Example 1 
Materials and Methods 
Mutant and wild-type p53 cDNAS, and Xdm-2 cDNA, 
were Subcloned into the Xenopus expression vector 
pSP64TS which provides Xenopus globin 3' and 5' untrans 
lated regions that Significantly improve translation 
efficiency, with the exception of p53'', which was used 
in pBS-SK (Stratagene). Capped mRNA was transcribed in 











microinjections (2 to 5 ml) and f-galactosidase assays were 
performed as previously described (Vize et al., 1991). 
Embryos were staged according to P. Nieuwkoop and J. 
Faber (Nieuwkoop and Faber, 1994). 
Embryos were fixed in MEMFA, stained for 
f-galactosidase activity (Vize et al., 1991) and processed in 
one of two ways. Some specimens were stained for anti 
bodies 2G9 (neural), 12/101 (muscle), 3G8 (pronephros), or 
EPA (epidermis) using whole-mount immunocytochemistry, 
embedded in JB-4 (Polysciences), sectioned at 5u, and 
counterstained with SytoxTM green (Molecular Probes) or 
hematoxylin and eosin (Sigma). Other specimens were 
embedded in Paraplast, Sectioned at 10u, and Stained for 
antibodies 2G9, 12/101, or 3G8 using serial-section immu 
nochemistry. This procedure yielded better penetration of 
the antibody into the Specimens. 
RT-PCR: Embryos were injected with 0.5 ng p53-'’ 
into the marginal Zone of all four cells at the four cell-Stage; 
control embryos were uninjected. Total RNA was extracted 
from 5 embryo equivalents at Stages 6, 10.5, and 13 and 
reverse transcribed. PCR was performed using one tenth of 
each reverse transcription reaction, Taq polymerase, 1 Ci of 
P-dATP, and primer sets listed below; cycle temperatures 
were 92 C., 55° C., and 72° C.; EF-1a for 16 cycles; 
goosecoid and brachyury for 19 cycles. Primer Sets were as 
follows: EF-1C.: CAGATTGGTGCTGGATATGC (SEQ ID 
NO:1) and ACTGCCTTGATGACTCCTAG (SEQ ID 
NO:2); goosecoid: ACAACTGGAAGCACTGGA (SEQ ID 
NO:3) and TCTTATTCCAGAGGAACC (SEQ ID NO:4); 
brachyury: GGATCGTTATCACCTCTG (SEQ ID NO:5) 
and GTGTAGTCTGTAGCAGCA (SEQID NO:6) One fifth 
of each PCR reaction was then electrophoresed on a 5% 
non-denaturing acrylamide gel and autoradiographed. 
Example 2 
Blocking Endogenous p53 Function in Xenopus 
Embryonic Cells 
In order to inactivate the maternal Stockpile of Xenopus 
p53, mRNA encoding a dominant-negative mutant form of 
p53 was introduced into developing embryos by microin 
jection. Synthetic mRNA encoding a dominant-negative 
form of human p53, p53'-' (Sun et al., 1994), was 
microinjected into a single blastomere in the presumptive 
mesoderm of 32-cell stage embryos along with mRNA 
encoding nuclear f3-galactosidase as a lineage tracer (Vize et 
al., 1991). These embryos were then raised to tadpole Stages, 
fixed, and Stained for f3-galactosidase activity (FIG. 1). 
Injection of B-galactosidase mRNA alone had no effect on 
development (Table 2); and in Such control experiments, 
B-galactosidase-positive cells were found evenly incorpo 
rated into axial. However, in embryos co-injected with 
p53' mRNA, the B-galactosidase-positive cells derived 
from the injected blastomere were found to be clustered into 
large cell masses, with no organization into axial Structures 
(FIG. 1; Table 2). 
TABLE 2 
Frequency of developmental tumor formation in response to ectopic 
eXpression of tumor-suppressors Or proto-Oncogenes. 
Injected mRNA Tumor Frequency N # Expts. 
0.5 ng f-gal O% 66 8 
0.5 ng p53Th280 67% 12O 2 
0.5 ng p53TP248 71% 34 2 
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TABLE 2-continued 
Frequency of developmental tumor formation in response to ectopic 
expression of tumor-suppressors or proto-oncogenes. 
Injected mRNA Tumor Frequency N # Expts. 
0.5 ng Hp53 O% 94 2 
0.5 ng Xp53 O% 38 1. 
1.0 ngxWT1 O% 106 11 
1.5 ng p53His17s 54% 114 2 
1.5 ng Xdm-2 30% 249 4 
Table 2. Wild-type tumor suppressors p53 (both human and Xenopus) and 
WT1 (Xenopus) do not induce tumor formation. Mutant p53 and wild-type 
Xdim-2 cause developmental tumors in a large percentage of injected 
embryos. The distribution of B-galactosidase-positive cells (see Table 3 
and FIG. 2A) was used to score the frequency of tumor formation, and 
tumor phenotypes were confirmed by histology. p53''' was not cloned 
into the expression vector 64TS and mRNA was generated from pBS, such 
mRNA will have a significantly lower translation efficiency (Vize et al., 
1991), which may explain the reduced frequency of tumor formation for 
this mutant. Abbreviations: f-gal, f-galactosidase; Xp53, Xenopus wild 
type p53: Hp53, human wild-type p53; xWT1, Xenopus wild-type WT1 
(Carroll and Vize, 1996). 
TABLE 3 
Wild-type p53 rescues the mutant p53 phenotype. 
# of 
Injected mRNA(s) Tumor Freq N Expts. 
125 pg. p53th 280 66% 249 8 
125 pg. p53"' + 500 pg Xenopus p53 30% 113 5 
125 pg. p53"' + 500 pg human p53 32% 128 4 
Table 3. The distribution of B-galactosidase-positive cells (as shown in 
FIG. 2A and FIG. 2B) was used to score the frequency of tumor formation 
in this assay, and tumor phenotypes were confirmed by histology. Four 
fold overexpression of either Xenopus or human wild-type p53 reduced 
tumor frequency by more than half. 
Histological analysis revealed that the cell masses formed 
by cells expressing p53" resembled tumors in a number 
of ways. The cell masses were nucleated and the cells within 
them were of approximately normal size and retained large 
numbers of yolk platelets, reminiscent of undifferentiated 
cells (FIG. 1). Furthermore, abnormal nuclear morphologies 
were observed (FIG. 1), and the undifferentiated cell masses 
were Sometimes Surrounded by an epithelial capsule and 
were often adjacent to large deposits of extracellular matrix. 
Immunohistochemistry with antibodies that detect neural 
(FIG. 1), muscle-, epidermal- or pronephric-specific anti 
gens failed to detect expression of any markers of terminal 
differentiation within p53'-induced tumors. These cells 
remained undifferentiated through the latest Stage examined 
(the feeding tadpole stage). As these tumors are derived from 
embryonic cells that have failed to differentiate, rather than 
from cells that have undergone dedifferentiation, they can be 
classified as blastomas, or undifferentiated embryonic 
derived tumors. 
Blocking p53 activity did not overtly interfere with or 
promote proliferation. AS Xenopus early development pro 
ceeds without growth, cell division results in the formation 
of smaller and smaller cells with each cell cycle. When a 
Single blastomere was injected with mutant p53, it gave rise 
to tumors containing hundreds of cells of approximately 
normal size, indicating that they have undergone a normal 
number of cell divisions. Although Some tumor nuclei may 
be pycnotic, extensive apoptosis was not triggered by block 
ing p53 activity, as evidenced by the continued presence of 
B-galactosidase-positive tumor cells. These observations 











hyperproliferation, but rather is the result of the failure of 
cells to be incorporated into normal tissues and to undergo 
differentiation. 
The phenotype elicited by mutant p53 was not due to 
non-specific effects caused by mRNA toxicity, as overex 
pression of wild-type human or Xenopus p53 did not induce 
tumor formation or inhibit normal differentiation (Table 2). 
While it has been previously reported that overexpression of 
wild-type Xenopus p53 results in cell cycle arrest (Hoever et 
al., 1994), the doses required to elicit such effects were 
extremely high, the lowest dose being more than double the 
highest dose injected here. In this Study, injections of up to 
1 ng of Xenopus or human wild-type p53 did not elicit cell 
cycle arrest or tumor formation. Likewise, injection of 
B-galactosidase mRNA alone, even at very high doses, had 
no effect on development (Table 2). Furthermore, no tumors 
have been reported in Xenopus embryos in previous Studies 
where other gene products were ectopically expressed, 
including other tumor-Suppressors such as APC (Vleminckx 
et al., 1997) and WT1 (Table 2), proto-oncogenes such as jun 
(Dong et al., 1996) and ras (Whitman and Melton, 1992), 
Viral oncogenes Such as polyoma middle T (Whitman and 
Melton, 1989) and v-ras (Whitman and Melton, 1992), or 
cyclins such as cyclin B2 (Hartley et al., 1996). 
Example 3 
Wild-type p53 Suppresses the Tumor-inducing 
Activity of Mutant p53 
Although mutant human p53 was overexpressed in these 
experiments, Xenopus p53 is Similar in Structure and func 
tion to human p53 and can form functional heterotetramers 
with human p53 (Tchang et al., 1993; Wang et al., 1995). If 
the mutant p53 blocks differentiation by oligomerizing with 
and inhibiting the activity of the endogenous Xenopus p53 
protein, the effect should be abrogated by coinjection with 
exceSS wild-type p53. Indeed, when an excess of either 
human or Xenopus wild-type p53 was coinjected with 
p53", the frequency of tumor formation was dramati 
cally reduced (FIG. 2 and Table 3). Considering that p53 
functions as a tetramer, most oligomers formed from a 4:1 
mixture of wild-type to mutant p53 protein will contain at 
least one mutant Subunit. This fact, in addition to the 
enhanced stability of mutant p53 proteins (Olson and 
Levine, 1994; Blagosklonny et al., 1995) may explain the 
inability of wild-type p53 to completely rescue the tumor 
phenotype. 
Example 4 
Different p53 Mutants Elicit a Similar 
Developmental Phenotype 
It is possible that the tumor phenotype was the result of an 
activity unique to p53". Therefore, the activity of other 
p53 dominant-negative mutants was evaluated using iden 
tical protocols. The original mutant tested, p53", dis 
rupts an essential base contact in the DNA-binding domain 
(Sun et al., 1994; Cho et al., 1994). Another mutant, 
p53'", disrupts DNA binding by eliminating essential 
minor groove contacts (Cho et al., 1994). Expression of 
p53' elicited a tumor phenotype identical to that of 
p53' in terms of frequency (Table 2), size, gross 
morphology, and histology (FIG. 3). A third mutant, 
p53''' which disrupts protein folding in the DNA 
binding domain (Cho et al., 1994), also elicited a similar 
tumor phenotype (FIG. 3, Table 2). 
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When embryos were injected into the presumptive somitic 
meSoderm, cells expressing a dominant-negative p53 were 
often displaced dorsally and lay adjacent to the neural tube 
just below the epidermis (FIG. 3). In many instances, such 
tumors were integrated into the differentiated cells of the 
adjacent epidermis or neural tube (FIG.3). Many tumors had 
asSociated melanocytes, either Superficial or integrated. The 
only other tissue in this region of the embryo with which 
melanocytes are commonly associated is the neural tube. In 
many cases where tumors were found lateral to the neural 
tube, the Somite on the injected Side of the embryo was 
restricted ventrally and greatly reduced in size (FIGS. 1 and 
3). Although it is possible that this reduction of the somite 
may be a result of tissue distortion caused by the presence 
of the tumor, it is more likely due to the failure of p53'- 
expressing cells to differentiate and consequent failure of 
these cells to contribute to the Somitic tissue. 
Tumors were also, though more rarely, found associated 
with mesodermal tissueS Such as Somite and pronephroS 
(FIG. 4). Because of the association of tumors with a number 
of different tissues, the ability of p53' expression to 
block differentiation was tested in Several cell lineages. 
Expression of p53" inhibited differentiation and elicited 
tumor formation in presumptive Somite, brain, Spinal cord, 
pronephros, and epidermal lineages when assayed by his 
tology and immunohistochemistry. Tumors derived from all 
cell types were similar to those described above for pre 
Sumptive Somite. 
Example 5 
Ectopic Xdim-2 Causes Tumor Formation 
The observation that wild-type p53 can block the activity 
of a mutant protein and that three different p53 mutants 
induce Similar tumors argues that the mutant human p53 
proteins block differentiation by inhibiting the activity of 
endogenous Xenopus p53. However, it is possible that these 
different proteins possess a common gain-of-function 
(neomorphic) activity and act via other proteins not nor 
mally associated with wild-type p53. The inventors there 
fore Sought to repress p53 activity without introducing 
mutant proteins. 
The murine double minute-2 (mdm-2) gene encodes an 
oncoprotein which binds to and inhibits the activity of the 
p53 transcriptional activation domain (Kussie et al., 1996; 
Momand et al., 1992). In order to eliminate p53 activity, 
mRNA injection was used to overexpress the XengpuS 
ortholog of mdm-2, Xdim-2 (Kussie et al., 1996), in devel 
oping embryos. The expression of Xdm-2 during normal 
Xenopus development has not yet been described, however 
the developmental expression of this gene is not relevant to 
the experiments described here, as microinjected Xdm-2 
was used only to interfere with the maternal Stockpile of 
p53, not endogenous Xdm-2. 
Overexpression of Xdm-2 mRNA elicited a tumor phe 
notype similar to that of mutant p53 (FIG. 3), although at a 
lower frequency (Table 2). These tumors were again iden 
tified initially by the failure of 3-galactosidase-positive cells 
to incorporate normally into axial Structures of the embryo. 
Tumors resulting from Xdm-2 overexpression were in gen 
eral smaller than those elicited by mutant p53; however, 
histological analysis revealed that Xdm-2-induced tumors 
were Similar in morphology to those resulting from mutant 
p53 expression (FIG. 3). Xdm-2-induced tumors tended to 
be located in aberrantly dorsal positions, contained yolk 
filled, nucleated cells, and were Sometimes integrated into 











It is possible that Xdm-2 induces tumors at a lower 
frequency than mutant p53 because of differences in protein 
Stability, Stoichiometry of inhibitory mechanisms, or 
because Xdm-2 only possesses a Subset of the activities of 
mutant p53. Xdm-2 may induce tumors by blocking endog 
enous p53 activity, while mutant p53 proteins may function 
both by blocking endogenous p53 and by gain-of-function 
activities (Dittmer et al., 1993). The early lethality observed 
in mdm-2 null mice can be rescued by generating Such mice 
in a p53 null background, arguing that the only essential 
function of mdm-2 during normal development is the regu 
lation of p53 activity (Montes de Oca Luna et al., 1995; 
Jones et al., 1995). Given this observation, it would seem 
that the Xdm-2 induced developmental tumors represent the 
minimal consequence of blocking p53 activity in Xenopus. 
Example 6 
Mutant p53 Does Not Interfere with the Mid 
Blastula Transition 
In Xenopus embryos, the first 12 cell cycles do not 
contain G1 or G2 phases, the cell cycle acquires these phases 
only after the mid-blastula transition (MBT), concomitant 
with the onset of Zygotic gene expression and the loSS of cell 
cycle synchrony (Newport and Kirschner, 1982; Newport 
and Kirschner, 1982b). One possible role for p53 in early 
amphibian development could be to implement G1 and G2 
cell cycle control at the MBT. In order to examine this 
possibility, the MBT was analyzed in embryos injected with 
p53' into all cells at the four-cell stage. Zygotic tran 
scription was activated normally (FIG. 5) and the cell cycle 
became asynchronous at the MBT in embryos expressing 
p53 in all cells, indicating that the MBT occurred nor 
mally. Not only does general transcriptional activation com 
mence normally, as indicated by the activation of a house 
keeping gene, EF-1a (Krieg et al., 1989), but mesodermal 
gene expression also commences normally, as evidenced by 
the activation of Brachyury (Smith et al., 1991) and Goosec 
oid (Cho et al., 1991) expression. This indicates that the 
mutant p53 is not blocking mesoderm induction. Rather, 
mutant p53 seems to be acting by blocking cells ability to 
act on these Signals and differentiate into mesoderm. 
Example 7 
A Role for p53 in Development 
Taken together, the results presented herein Suggest a 
crucial role for p53 in early Xenopus development. 
Although dominant-negative p53 mutants may have gain 
of-function activities, the Xdm-2. results argue that the 
mutant proteins are likely to be acting by interfering with 
endogenous p53. If a gain-of-function activity is 
responsible, this activity must be shared by three different 
mutants and a distinct tumor phenotype must be elicited by 
ectopic Xdm-2. Although this would be an extraordinary 
coincidence, the inventorS aim to eliminate this possibility 
by interfering with p53 activity by other methods. The most 
likely explanation for the data presented here is that p53 
activity is essential for normal development in Xenopus, and 
that interfering with p53 function results in blocking the 
ability of embryonic cells to differentiate. 
How can p53 be essential to frog development but dis 
pensable during murine development? One possibility is that 
p53 is required for a developmental process that is not 
utilized during murine development. The mostly likely can 
didate process was the mid-blastula transition, which is 
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critical to frog development but has no true equivalent in 
mice. However, the data shown in FIG. 5 indicate that the 
MBT occurs normally and So cannot explain the incongru 
ence between mouse and frog observations. The Xenopus 
embryonic cell cycle undergoes a Second transition period a 
few cycles after the MBT. This second transition is known 
as the early gastrula transition (EGT) and is characterized by 
a significant lengthening of the gap phases of the cell cycle 
(Howe et al., 1995). This lengthening may reflect the acqui 
Sition of additional check points or other cell cycle 
properties, and it may be these additional properties which 
are essential for differentiation. The timing of the EGT is 
consistent with the defects observed in response to blocking 
p53 activity, as the first Stage at which defects have been 
identified are early neurulae, shortly after the end of gas 
trulation. 
Xenopus contain a large maternal Stockpile of p53 mRNA 
and protein (Cox et al., 1994), while mammalian embryos 
express only low levels of p53 (Komarova et al., 1997) and 
maternal stocks of p53 have not yet been described. A 
maternal Stockpile of p53 protein in p53 null mice cannot 
explain the lack of an early effect on mouse development as 
p53 null mice can be crossed and produce viable offspring 
(Armstrong et al., 1995). It is possible that the Xenopus 
Stockpile is utilized for Some as yet uncharacterized, but 
essential, developmental process. 
Another possibility is that mice have genetic redundancies 
not present in frogs, making Xenopus more Sensitive to p53 
inhibition. For example, in mammals mutation of MyoD or 
Myf-5 does not disrupt myogenesis, but combination of the 
two mutants does (Rudnicki et al., 1993). The detailed 
analysis of MyoD alone would not have predicted a role for 
this important gene in muscle development in mice. Another 
useful example is the activins, which appear to be essential 
for mesoderm induction in Xenopus (Hemmatti-Brivanlou 
and Melton, 1992) but which are not required for mesoderm 
formation in mice (Matzuk et al., 1995a;. 1995b). Once 
again, excluding a role for this gene in development based 
Solely upon the mouse mutant phenotype would have been 
premature. Lower vertebrates may have leSS complex redun 
dancies protecting proliferation and differentiation, making 
them more dependent on p53 function. It is interesting to 
note that developmental defects in p53 null mice occur at 
different frequencies in different genetic backgrounds 
(Armstrong et al., 1995; Sah et al., 1995), implying that at 
least Some Such functional redundancies exist, and that 
without these redundancies p53 function is necessary for 
normal development. 
High level expression of a potent dominant-negative p53 
during early murine development may well have more 
penetrant effects than targeted p53 disruption, especially if 
mutant proteins possess a weak gain-of-function activity in 
addition to their dominant-negative activity. The commonly 
used p53' transgenic mice express a rather weak tem 
perature sensitive mutant under the control of the p53 
promoter (Harvey et al., 1995). As mutant proteins must be 
present in excess to interfere effectively with wild-type 
protein (Gottlieb and Oren, 1996), these mice may not really 
address this question. The inventors are presently examining 
the activity of p53" on very early murine development 
to explore this issue. If the existence of genetic redundancies 
is the reason for the lack of a penetrant phenotype in p53 null 
mice, the lack of Such redundancies in Xenopus may provide 
a System in which the redundant genes can be identified. 
Microinjection of mutant p53 mRNA plus pools of mRNAS 
from mammalian cell lines and Screening for the ability of 












identification of Such genes. The identification of Such 
genes, will be extremely relevant to the Study of human 
tumorigenesis. 
All of the compositions and/or methods disclosed and 
claimed herein can be made and executed without undue 
experimentation in light of the present disclosure. While the 
compositions and methods of this invention have been 
described in terms of preferred embodiments, it will be 
apparent to those of Skill in the art that variations may be 
applied to the compositions and/or methods and in the Steps 
or in the Sequence of Steps of the method described herein 
without departing from the concept, Spirit and Scope of the 
invention. More specifically, it will be apparent that certain 
agents which are both chemically and physiologically 
related may be Substituted for the agents described herein 
while the same or similar results would be achieved. All 
Such similar Substitutes and modifications apparent to those 
skilled in the art are deemed to be within the Spirit, Scope and 
concept of the invention as defined by the appended claims. 
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-continued 
SEQ ID NO 1 
LENGTH 2.0 
TYPE DNA 
ORGANISM: Homo sapiens 
<400 SEQUENCE: 1 
cagattggtg citggatatgc 
SEQ ID NO 2 
LENGTH 2.0 
TYPE DNA 
ORGANISM: Homo sapiens 
<400 SEQUENCE: 2 
actgccttga tigacitcc tag 
SEQ ID NO 3 
LENGTH 18 
TYPE DNA 
ORGANISM: Homo sapiens 
<400 SEQUENCE: 3 
acaactggaa goactgga 
SEQ ID NO 4 
LENGTH 18 
TYPE DNA 
ORGANISM: Homo sapiens 
<400 SEQUENCE: 4 
tottattoca gaggaacc 
SEQ ID NO 5 
LENGTH 18 
TYPE DNA 
ORGANISM: Homo sapiens 
<400 SEQUENCE: 5 
ggat.cgittat caccitctg 
SEQ ID NO 6 
LENGTH 18 
TYPE DNA 
ORGANISM: Homo sapiens 
<400 SEQUENCE: 6 
gtgtag totg tag cagoa 
What is claimed is: 
1. A method of Screening for agents that inhibit a block of 
p53-related embryonic cell differentiation comprising the 
Steps of: 
(i) providing an isolated, undifferentiated embryonic cell; 
(ii) blocking the function of p53 in said cell such that said 
cell fails to differentiate; 
(iii) contacting said cell with a candidate agent; and 
(iv) comparing the differentiation of Said contacted cell 
after Said contacting with the differentiation of Said cell 
in the absence of Said candidate agent; 
whereby an increase in differentiation indicates that Said 











2. The method of claim 1, further comprising the step of 
comparing the differentiation of Said cell after Said contact 
ing with the differentiation of said undifferentiated embry 
onic cell. 
3. The method of claim 1, wherein said cell is a mam 
malian cell. 
4. The method of claim 3, wherein said cell is a mouse 
cell. 
5. The method of claim 3, wherein said cell is a human 
cell. 
6. The method of claim 1, wherein said blocking is 
achieved by introducing into Said cell a nucleic acid encod 
ing a dominant negative mutant of p53. 
7. The method of claim 6, wherein said introducing is 
achieved via electroporation, microinjection, particle 
bombardment, lipoSome transfer or viral infection. 
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8. The method of claim 6, wherein said nucleic acid is a 
DNA 
9. The method of claim 6, wherein said nucleic acid is an 
RNA. 
10. The method of claim 1, wherein said candidate agent 
is polypeptide. 
11. The method of claim 1, wherein Said candidate agent 
is produced by a neighboring cell. 
42 
12. The method of claim 11, wherein said neighboring cell 
is a Second undifferentiated embryonic cell into which Said 
candidate.agent has been introduced. 
13. The method of claim 1, wherein differentiation is 
determined by culture of said undifferentiated embryonic 
cell in vitro under conditions where said cell differentiates. 
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